National Essential Drugs List
Islamic Republic of Afghanistan
Ministry of Public Health
General Directorate of Pharmacy
Avicenna Pharmaceutical Institute
Essential Drugs Department

December 2007
Preface

The policy of the MoPH of Islamic republic of Afghanistan includes ensuring that the population of Afghanistan has access to safe, effective, and affordable medicines to treat its main health problems. As a subset of the drugs included in the Licensed Drugs List (LDL), the Essential Drugs List (EDL) contains the medicines needed for adequately addressing the priority health problems defined in the MOPH’s Health Strategy, in particular the medicines needed for the successful implementation of the Basic Package of Health Services (BPoS) and the Essential Package of Hospital Services (EPHS). Many of the medicines contained in the ED are subsidized in some way by the MOPH to improve their availability to the Afghan people.

A previous version of the EDL was developed and published in 2003. The rapid pace of expansion of basic health services in Afghanistan since 2002, the changing internationally recommended treatment protocols for some diseases (e.g. malaria, TB, diarrhea…) and the presence of new emergent diseases (e.g. HIV, …) urged the MOPH to revise and adapt the existing EDL. Previously the EDL and and the LDL had been developed separately, and the unavoidable discrepancies between the final documents created confusion with some users. Therefore, the MOPH decided to entrust the revision of both documents to one committee, thus minimizing possible future discrepancies.

The LLD/EDL review committee also drafted the detailed procedures for inclusion of new medicines on the EDL, guidelines for adequate use of the lists and initiated the development of a database for tracking the updates and edits in the EDL. The procedures will facilitate the mechanism of inclusion new drug in EDL under logic and comprehensive methods, this procedure concentrate to the specific format which guarantees the inclusion of new drug by a scientific & transparent way.

I would like to express its appreciation to the members of the LDL/EDL review committee, who oversaw and managed the complicated process of updating the lists. The MOPH is also grateful to the many Afghan and international organizations and individuals who provided assistance and support in the process. We are especially grateful for the sustained technical and financial assistance of the United States Agency for International Development thought the Technical Support to the Central and Provincial Ministry of Public Health (Tech-Serve), implemented by Management Sciences for Health, and of the World Health Organization, Eastern Mediterranean Regional Office which allowed the successful revision, publication and distribution of the updated Essential Drugs List of Afghanistan.

The MoPH warmly recommends its partners in the public health sector, in particular those contributing to the implementation of the BPoS and EPHS, to use the EDL as official reference. It will facilitate the task of all those working with the MOPH to reach its goals and objectives of providing quality health services to the people of Afghanistan.

Dr. Said M. Amrin Fatimi
Minister of Public Health
Kabul, Afghanistan
December 2007
# TABLE OF CONTENTS

List of Contributors and Collaborators ................................................................. 4  
Abbreviations ........................................................................................................ 6  
Introduction ............................................................................................................ 7  
  1. Short history .................................................................................................... 7  
  2. Objectives of 2007 Update ............................................................................ 7  
  3. Transparent review process ........................................................................... 7  
  4. Classifications of drugs .................................................................................. 8  
  5. Procedures for inclusion of new products ....................................................... 9  
  6. Computerization ............................................................................................ 9  
  7. Drug listing in the EDL .................................................................................. 9  
  8. Detailed instructions for use of the EDL ....................................................... 10  
Anatomo Therapeutic Chemical Classification ..................................................... 12  
Reference table for Vitamins and Minerals Supplements ........................................ 34  
National Family Planning Program List ............................................................... 36  
National Post Partum Hemorrhage Program List ................................................ 36  
National HIV/AIDS Program List ........................................................................ 37  
National Dependency Substitution Program List ............................................... 38  
National Malaria and Leishmania Program List .................................................. 39  
National Tuberculosis Program List .................................................................... 40  
National Leprosy Program List ............................................................................ 40  
ANNEX 1: Procedure for Application for Inclusion of Medicines on the Essential Drugs List 41
List of Contributors and Collaborators

The following individuals and organizations contributed to different stages in revising of the National EDL & LDL

Core EDL/LDL committee members:

Dr. Faizullah Kakar, Deputy Minister of MoPH
Dr. Aisha Noorzaee, Director of Avicen Pharmaceutical Institute MOPH
Dr. Paul Ickx, MSH/Tech-Serve
Dr. M. Rafi Rahmani, Kabul Medical University
Dr. M. Zafar Omari, MSH/Tech-Serve
Dr. Abdul Samad Omar, MoPH
Dr. Abdul Jalil Rassoli, MoPH
Dr. Fahima Habib, MoPH

Contributing EDL/LDL committee members:

Prof. Said Ali Asghar Payman, consultant of the Second Vice President
Drs. Nadera Hayat Burhani, Deputy Minister for Reproductive and Child Health, MOPH
Ms. Gulalai Safi Member of Parliament
Ms. Fauzia Rauofi Member of Parliament
Dr. Aqela Noori MoPH
Dr. Jamahir Anwari MoPH
Prof. Dr. Ghzanfar MoPH
Prof. Dr. Ramzan Payanda Faculty of Pharmacy
Prof. Abdul Hai Momeni Aghanistan academy of Science
Prof. Dr. Qumarudin Saifi, University of Kabul
Prof. M. Nasim Sediqi Faculty of Pharmacy
Dr. Abdul Rahim Pashtonyar MoPH
Dr. M. Kazim Namei MoPH
Dr. Abdul Wali MoPH
Dr. Khalil Khakzad, MoPH
Dr. M. Nazir Haidarzad MoPH
Dr. Khan Aqa Karim Ghazi, MoPH
Dr. Zakia Adel, MoPH
Dr. M. Ashraf Mashkoor, MoPH
Dr. Aziza Yousuf, MoPH
Dr. Alia Abrahamzai, MoPH
Dr. M. Amin, MoPH
Dr. Karima Mayar, MoPH
Dr. Saeed Azimi WHO
Dr. Sajid WHO
Dr. Abdulah Masoud MSH
Dr. Abdul Khalilq Hakimpur, MoPH
Dr. Masoom Saboorzai, MoPH
Mr. Joseph Rittman HIV/AIDS Department
Dr. Saifulla HIV/AIDS Department
Dr. Najibullah Safi, MoPH
Dr. Ajmal Yadgari, MoPH

Version of 15 December 2007
Dr. Aqa Muhammad Stankazai, MoPH
Dr. Humayon Taherian, MoPH
Dr. Ghuphran Kayhan, MoPH
Dr. Fawad Furmoly, MoPH
Dr. Najibullah Dabiry, MoPH
Dr. Sardar M. Kashmiri, MoPH
Dr. Mohibullah Mohib, MoPH
Dr. Hydayatullah Salehi, MoPH
Dr. M. Afzal Qaseem, MoPH
Dr. M. Aref Abrahimi, MoPH
Dr. Sarwar, MoPH
Dr. Qudsia Wali, Academy of Science
Dr. M. Raziq, MoPH
Mr. M. Fahim MSH/TechServe
Dr. Hafizullah Qurishy, MoPH
Mr. Rahmudin Private sector representative
Dr. Sultan Masoud, MoPH
Mr. Akram Zaki, MSH/TechServe

Contributing MoPH Departments and partner institutions:

- HMIS, MoPH
- HIV/AIDS, MoPH
- Mental Health, MoPH
- Family Planning, MoPH
- Reproductive Health, MoPH
- IMCI, MoPH
- Malaria & Leishmania, MoPH
- Policy & Planning, MoPH
- National Tuberculosis Institute, MoPH
- World Health Organization, Eastern Mediterranean Regional Office
- Management Sciences for Health, Tech-Serve Progra
Abbreviations

ATC  Anatomo-Therapeutical-Chemical (classification)
BAN  British Approved Name
BNF  British National Formulary
BPHS Basic Package of Health Services for Afghanistan
DG   Director General
EDL  Essential Drugs List of Afghanistan
EMRO Eastern Mediterranean Regional Office (WHO)
EPhMRA European Pharmaceutical Market Research Association
EPHS Essential Package of Hospital Services for Afghanistan
GD   General Directorate
GOA  Government of Afghanistan
INN  International Non-proprietary Name
LDL  Licensed Drugs List of Afghanistan
MLEM Model List of Essential Medicines (WHO)
MOPH Ministry of Public Health
MSH  Management Sciences for Health
NGO  Non-Governmental Organization
PBIRG Pharmaceutical Business Intelligence and Research Group
TECH-SERVE Technical Support to the Central & Provincial Ministry of Public Health
USAID United States Agency for International Development
USAN United States Adopted Name
WHO  World Health Organization
Introduction

1. Short history

In 2003, the MOPH published a previous version of the National Essential Drug List (EDL) for Afghanistan. The EDL contains all the drugs recommended for use in the BPH, EPHS and the MOPH’s national programs.

Given the quick development and expansion of the health service delivery system in Afghanistan since 2003, including the development of new treatment protocols and updated WHO recommendations for several diseases, the need for updating the EDL became adamant. The MOPH constituted a Review Committee in May 2007, consisting of clinical and pharmaceutical experts from the MOPH, major hospitals, teaching institutes, international agencies, NGOs and the private sector. Between May and December 2007, the committee met regularly, and individual committee members took responsibility for the in-depth revision of certain parts of the LDL/EDL with sub-committees, enlarging the consultative process to an even larger group of experts from the different MOPH task forces, training institutes, NGOs and international organizations. Late October 2007, a draft was presented in a 2 day workshop, attended by over 200 participants including senators of the Afghan parliament, provincial health directorates, pharmacy and medical specialists, provincial pharmacy officers, and representatives of NGOs working in health and of the private sector. The draft was scrutinized and finalized through intensive group work.

2. Objectives of 2007 Update

The main objectives of the review process in 2007 were:
1. To achieve complete consistency between the BPHS-EPHS-EDL-LDL documents, based on a rational selection of essential drugs.
2. Elaborate clear Terms of Reference for the Pharmaceutical Review Committee, not only for this exercise, but also for revisions in the future
3. Define a detailed and transparent review process that can be used for future revisions.
4. Define detailed and transparent procedures to control possible exceptions to the EDL with administrative and budgetary methods. Similar procedures should apply to requests for deletion, or addition of a product that is on the EDL.

3. Transparent review process

Under guidance and supervision of the DG Pharmacy, the Review Committee adhered to a transparent review process in all stages of the revision, in order to allow future reference to the decisions made:
1. clear definition of what documents need to be produced by the process, in this case, the EDL and LDL, and clear procedures for inclusion of new drugs in the lists;
2. agreement of the Working Principles: how to manage the Review Task force and the inclusive consultation of interested parties/stakeholders, without creating a slow and cumbersome process. Realistic deadlines for different stages in the review process were set.
3. Definition of the reference works that should guide the review process:
   • The existing EDL;
   • The WHO Model List of Essential Medicines (MLEM) as a main guide on efficacy, safety and quality;
• The Afghan BPHS/EPHS documents;
• Recently updated treatment recommendations from MOPH departments and programs;
• Product lists of recognized international suppliers are a good guide to evaluate availability and cost;
• British National Formulary and Martindale were used as references where the above documents failed to provide enough information.

4. Define specific selection criteria for inclusion in the EDL
• Drugs listed on the WHO MLEM, can be included to ensure efficacy, safety and quality;
• Drugs listed in the BPHS/EPHS should be included;
• Drugs recommended in standard treatment protocols should be included;
• Included drugs should be available in Afghanistan to ensure availability;
• Included drugs should be available from recognized international suppliers which ensures availability and affordable cost;
• Drugs already donated by international donors should be included which ensures availability and affordable cost for certain essential drugs;

4. Classifications of drugs

The medicines in the EDL are grouped according to the Anatomo Therapeutical Chemical (ATC) classification, promoted by the WHO Collaborating Centre for Drug Statistics Methodology. The drugs are divided into fourteen main groups (1st level), with one pharmacological/therapeutic subgroup (2nd level). The 3rd and 4th levels are chemical/pharmacological/therapeutic subgroups and the 5th level is the chemical substance. The 2nd, 3rd and 4th levels are often used to identify pharmacological subgroups when that is considered more appropriate than therapeutic or chemical subgroups. For example, Ampicilline is classified as follows:

J Antiinfectives for systemic use (main group)
  J01 Antibacterials for systemic use (therapeutical subgroup)
  J01C Beta-Lactam Antibacterials, Penicillins (chemical subgroup)
  J01CA Penicillins with extended spectrum (chemical subgroup)
  J01CA01 Ampicillin (chemical substance)

Thus each chemical substance in the EDL has its 7-digit ATC code. A chemical substance can have more than one ATC code, if it is used for different therapeutic purposes. The same substance listed under different administration forms or presentations will have the same ATC code, if the different forms are used for the same therapeutical purpose. The ATC code is not a unique identifier for each individual drug included in the EDL.

Where it exists, the International Non-proprietary Name (INN) is used for the chemical substance. When this is not available, either the United States Adopted Name (USAN) or the British Approved Name (BAN) is chosen.

The ATC classification was chosen because it contains also Defined Daily Doses for many of the products listed; it will facilitate studies on consumption of medicines in Afghanistan; it will allow comparing studies on Afghanistan’s pharmaceutical system with other countries; and it also has an equivalent classification system for herbal medicines and veterinary
products. It is also flexible enough to allow temporary classification of a group of products, until a specific code is found.

The ATC classification is updated regularly by WHO. The MOPH decided to use the January 2007 version, and has adapted the system for use in Afghanistan. The adapted ATC is available from the MOPH on request. The MOPH will not annually update the ATC classification used in Afghanistan, but most likely do a 5-yearly update.

5. Procedures for inclusion of new products

The committee drafted detailed instructions for updating and including new products in the EDL. The request form and detailed user guides are given in Annex 1.

6. Computerization

The GD Pharmacy will track future updates and changes in the EDL through a database. Presently the database contains all the generic names of the drugs contained in the EDL and LDL, including recent deletions. Of each drug the following information is tracked:

- Classification code based on the WHO ATC classification, version of January 2007.
- International non-proprietary name, strength and presentation, to the extend possible matching the name used in the WHO ATC classification;
- Alternate generic name under which the drug is used in Afghanistan;
- Modal international indicator price, where available;
- Indication whether the drug is included in the Essential Drugs List of Afghanistan;
- Indication whether the drug is this presentation and strength is used in BPHS and/or EPHS;
- Indication whether the drug is on the controlled substances list of Afghanistan, is available without prescription, is included in a special program of the MOPH (which may entail restriction in importation and use), and is included in the Model List of Essential Medicine of WHO.

Tracking the medicines through a database allows easy production of customized listings for different purposes, and also storing historical data on products no longer used. This database module may become the core of a more extended database, when the MOPH starts computerizing all registered drugs in Afghanistan.

7. Drug listing in the EDL

The EDL contains an ATC listing of medicines recommended for use in the public sector. Chemical substances are listed under their INN and preparation details, indicating whether at what level they are recommended for use in the BPHS and/or EPHS. If a substance is used for different therapeutic purposes, that substance will be listed under each corresponding group, with a different ATC code. Items are listed up to the 3rd level only. More detailed classification was deemed needlessly cumbersome.

The EDL also lists the items included in special lists separately, for use by specific programs of the MOPH. These items are part of the EDL, but some are restricted for use by the specific programs of the MOPH as indicated in the Special Programs Lists.

Version of 15 December 2007
8. Detailed instructions for use of the EDL

1. The EDL contains all items allowable for use in the public sector. The MOPH recommends limiting drug donations to items and strengths listed in the EDL. It contains all drugs recommended for use in the BPHS and EPHS.

2. Several drugs are listed for use only in special programs (e.g. opium tincture for substance abuse program, antiretroviral drugs for HIV program, misoprostol for post partum hemorrhage program, …). Please refer to the instructions for appropriate use under each program.

3. The following presentation forms are interchangeable, meaning that if one is mentioned, the others are allowable as well:
   a. Tablets and capsules for oral administration tab-cap. Retard or sustained realease tablets/capsules are not interchangeable with normal tablets/capsules.
   b. Creams and ointment and gel for topical administration;
   c. Solution and syrup and suspension and powder for oral administration. They are not interchangeable with oral tablets-capsules.
   d. Solution and powder for injectable solution. Aqueous and oily solutions are not interchangeable. Normal injections and retard, sustained release or long-acting injections are not interchangeable.

Examples:
Amoxicillin 250 mg capsule is listed, Amoxicillin 250 mg tablet is accepted as well
Bacitracin ointment is listed, Bacitracin cream is accepted as well
NOTE: if an oral form is listed, this does not mean that a topical or injectable form is accepted.

4. If the volume of a bottle or the weight of a container or tube is mentioned, they will often correspond to a full treatment of the most common patient population using that drug. The explicitly mentioned volume and weight are minimal limits, i.e. smaller containers will not be accepted, but larger containers are acceptable.

Examples:
Cotrimoxazole oral suspension 50ml is listed: cotrimoxazole 40ml is not acceptable, cotrimoxazole 60 ml or 100ml is acceptable

5. Vitamins and minerals are included in a two different sections:
   a. Individual vitamins and minerals are listed in the main list, with exact specifications. Most often these preparations are used for therapeutic purposes.
   b. Multivitamins with or without minerals are allowable, as long as the concentration of each active substance per unit dose (tablet, ml, 5ml, ..) falls within the limits for Supplement Daily Intake listed in the Reference Table for Vitamins and Minerals Supplements. Most often these preparations are used as dietary supplements.

6. Oral Rehydration Salts are listed in two forms: 20.5gr per liter and 27.9gr per liter. The 20.5gr per liter solution is recommended by WHO, and likewise by the MOPH. However, the 27.9gr per liter was formerly recommended and is still widely available. It will remain allowable in Afghanistan till December 2009, but all BPHS/EPHS implementers are suggested to change to the new solution as soon as possible.

Composition of ORS 20.5gr/liter:

Version of 15 December 2007
Composition of ORS 27.9gr per liter:

- Glucose: 20g
- Potassium chloride: 1.5g
- Sodium chloride: 3.5g
- Trisodium citrate dihydrate: 2.9g


8. Where to obtain copies and updates of the LDL

Printed copies of this version can be obtained from the MOPH/GD Pharmacy/API/Essential Drugs Department in Kabul. Contact person is Ms. Aisha Noorzayee, mobile phone: 070061337

Copies on CD of updated version can be obtained at the same address through the same contact person.

Updated versions will also be available on the website of the MOPH: [www.moph.gov.af](http://www.moph.gov.af).
### Essential Drugs List

#### Anatomo Therapeutic Chemical Classification

#### A- ALIMENTARY TRACT AND METABOLISM

##### A02- DRUGS FOR ACID RELATED DISORDERS

**A02A- ANTACIDS**

<table>
<thead>
<tr>
<th>Description</th>
<th>Formulation</th>
<th>Pharmacology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aluminium hydroxide 120mg + Magnesium trisilicate 250mg per tablet, oral</td>
<td>ingestion tablet-capsule [A02AD01]</td>
<td>PH,BHC,CHC,DH DH,PH,RH</td>
</tr>
<tr>
<td>Aluminium hydroxide 200mg + Magnesium hydroxide 200mg per tablet, oral</td>
<td>ingestion chewable tablet [A02AD01]</td>
<td>HP,BHC,CHC,DH DH,PH,RH</td>
</tr>
<tr>
<td>Aluminium hydroxide 225mg + Magnesium hydroxide 200mg per five milliliter,</td>
<td>in 200ml bottle, oral ingestion suspension-syrup-liquid [A02AD01]</td>
<td>BHC,CHC,DH</td>
</tr>
<tr>
<td>in 200ml bottle, oral ingestion suspension-syrup-liquid [A02AD01]</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aluminium hydroxide 500mg per tablet, oral ingestion chewable tablet [A02AB01]</td>
<td></td>
<td>BHC,CHC,DH</td>
</tr>
</tbody>
</table>

#### A02B- DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)

<table>
<thead>
<tr>
<th>Description</th>
<th>Formulation</th>
<th>Pharmacology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Omeprazole 20mg per capsule, oral ingestion tablet-capsule [A02BC01or]</td>
<td>PH,RH</td>
<td></td>
</tr>
<tr>
<td>Omeprazole 40mg per capsule, oral ingestion tablet-capsule [A02BC01or]</td>
<td>PH,RH</td>
<td></td>
</tr>
<tr>
<td>Omeprazole 40mg per vial, injection ampoule-vial [A02BC01or]</td>
<td>DH,PH,RH</td>
<td></td>
</tr>
<tr>
<td>Ranitidine 150mg per tablet, oral ingestion tablet-capsule [A02BA02or]</td>
<td>PH,RH</td>
<td></td>
</tr>
<tr>
<td>Ranitidine 25mg per milliliter, in 2ml ampoule, injection ampoule-vial [A02BA02inj]</td>
<td>PH,RH</td>
<td></td>
</tr>
<tr>
<td>Ranitidine 300mg per tablet, oral ingestion tablet-capsule [A02BA02or]</td>
<td>PH,RH</td>
<td></td>
</tr>
</tbody>
</table>

#### A03- DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS

##### A03B- BELLADONNA AND DERIVATIVES, PLAIN

<table>
<thead>
<tr>
<th>Description</th>
<th>Formulation</th>
<th>Pharmacology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Atropine sulfate 1mg per milliliter, in 1ml ampoule, injection ampoule-vial</td>
<td>[A03BA01inj]</td>
<td>DH,PH,RH</td>
</tr>
<tr>
<td>Butylscopolamine 10mg per tablet, oral ingestion tablet-capsule (Hyoscine)</td>
<td>[A03BB01or]</td>
<td>DH,PH,RH</td>
</tr>
<tr>
<td>Butylscopolamine 20mg per milliliter, in 3ml ampoule, injection ampoule-vial (Hyoscine)</td>
<td>[A03BB01inj]</td>
<td>DH,PH,RH</td>
</tr>
</tbody>
</table>

##### A03F- PROPULSIVES

<table>
<thead>
<tr>
<th>Description</th>
<th>Formulation</th>
<th>Pharmacology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metoclopramide 10mg per tablet, oral ingestion tablet-capsule [A03FA01or]</td>
<td></td>
<td>BHC,CHC,DH   DH,PH,RH</td>
</tr>
<tr>
<td>Metoclopramide 5mg per milliliter, injection ampoule-vial [A03FA01inj]</td>
<td></td>
<td>BHC*,CHC,DH  DH,PH,RH</td>
</tr>
</tbody>
</table>

#### A06- LAXATIVES

<table>
<thead>
<tr>
<th>Description</th>
<th>Formulation</th>
<th>Pharmacology</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bisacodyl 5mg per tablet, oral ingestion tablet-capsule [A06AB02or]</td>
<td></td>
<td>DH,PH,RH</td>
</tr>
</tbody>
</table>

**Version of 15 December 2007**
A07A-  ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS
A07A-  INTESTINAL ANTIINFECTIVES
Nystatin 100000IU per milliliter, oral topical drop [A07AA02or] BHC,CHC,DH DH,PH,RH
Nystatin 100000IU per tablet, oral ingestion tablet-capsule [A07AA02or] BHC,CHC,DH DH,PH,RH
Nystatin 500000IU per tablet, oral ingestion tablet-capsule [A07AA02or] BHC,CHC,DH DH,PH,RH

A07B-  INTESTINAL ADSORBENTS
Activated charcoal 1gr per tablet, oral ingestion tablet-capsule [A07BA01or] DH,PH,RH
Activated charcoal 125mg per tablet, oral ingestion tablet-capsule [A07BA01or]
Activated charcoal 250mg per tablet, oral ingestion tablet-capsule [A07BA01or] HP,BHC,CHC,DH DH,PH,RH
Activated charcoal 500mg per tablet, oral ingestion tablet-capsule [A07BA01or] HP,BHC,CHC,DH DH,PH,RH

A07C-  ELECTROLYTES WITH CARBOHYDRATES
Oral rehydration salts 20.5gr per litre, in 1lit sachet, oral ingestion powder (ORS) (ORS) [A07CA01] HP,BHC,CHC,DH DH,PH,RH
Oral rehydration salts 27.9gr per litre, in 1lit sachet, oral ingestion powder (ORS) (ORS) [A07CA01] HP,BHC,CHC,DH DH,PH,RH

A10-  DRUGS USED IN DIABETES
A10A-  INSULINS AND ANALOGUES
Insulin isophane (NPH) intermediate 100IU per milliliter, in 10ml vial, injection ampoule-vial [A10AC01inj] PH,RH
Insulin isophane (NPH) intermediate 40IU per milliliter, in 10ml vial, injection ampoule-vial [A10AC01inj] RH
Insulin soluble fast 100IU per milliliter, in 10ml vial, injection ampoule-vial [A10AB01inj] PH,RH
Insulin soluble fast 40IU per milliliter, in 10ml vial, injection ampoule-vial [A10AB01inj] RH

A10B-  BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Glibenclamide 5mg per tablet, oral ingestion tablet-capsule [A10BB01or] PH,RH
Metformin 500mg per tablet, oral ingestion tablet-capsule [A10BA02or] PH,RH

A11-  VITAMINS
A11A-  MULTIVITAMINS, COMBINATIONS
Multivitamins and other minerals, incl. combinations (see multivitamin table) [A11AA03] HP,BHC,CHC,DH DH,PH,RH
Multivitamins and trace elements (see multivitamin table) [A11AA04] HP,BHC,CHC,DH DH,PH,RH
Multivitamins, other combinations (see multivitamin table) [A11AB00] HP,BHC,CHC,DH DH,PH,RH

A11C-  VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO
Colecalciferol 600000IU per milliliter, injection ampoule-vial (Vit D3) [A11CC05] DH,PH,RH

Version of 15 December 2007
Retinol (oily) 100000IU per milliliter, oral ingestion solution (Vit A) [A11CA01or] RH
Retinol 100000IU per ampoule, injection ampoule-vial (Vit A) [A11CA01inj] RH
Retinol 10000IU per tablet, oral ingestion tablet-capsule (Vit A) [A11CA01or] HP,BHC,CHC,DH DH,PH,RH
Retinol 200000IU per tablet, oral ingestion tablet-capsule (Vit A) [A11CA01or] HP,BHC,CHC,DH DH,PH,RH

A11H- OTHER PLAIN VITAMIN PREPARATIONS
Pyridoxine 25mg per tablet, oral ingestion tablet-capsule (Vit B6) [A11HA02or] DH,PH,RH
Pyridoxine 40mg per tablet, oral ingestion tablet-capsule (Vit B6) [A11HA02or] DH,PH,RH

A12- MINERAL SUPPLEMENTS
A12A- CALCIUM
Calcium gluconate 10% in 10ml ampoule, injection ampoule-vial [A12AA03inj] DH,PH,RH

A12C- OTHER MINERAL SUPPLEMENTS
Zinc sulfate 10mg per tablet, oral ingestion tablet-capsule [A12CB01]
Zinc sulfate 20mg per tablet, oral ingestion tablet-capsule [A12CB01]

B- BLOOD AND BLOOD FORMING ORGANS

B01- ANTIITHROMBOTIC AGENTS
Acetylsalicylic acid 100mg per tablet, oral ingestion tablet-capsule (Aspirin) (ASA) [B01AC06or] BHC*,CHC,DH DH,PH,RH
Acetylsalicylic acid 325mg per tablet, oral ingestion tablet-capsule (Aspirin) (ASA) [B01AC06or]
Enoxaparin 100mg per milliliter, injection solution [B01AB05inj] DH,PH,RH
Heparin 1000IU per milliliter, in 1ml ampoule, injection solution [B01AB01inj] PH,HH
Heparin 25000IU per milliliter, in 1ml ampoule, injection solution [B01AB01inj] PH,HH
Heparin 5000IU per milliliter, in 1ml ampoule, injection solution [B01AB01inj] PH,HH

B02- ANTIHEMORRHAGICS
Coagulation factor II, VII, IX, X per ampoule, injection ampoule-vial [B02BD01inj]
Coagulation factor VIII per ampoule, injection ampoule-vial [B02BD02inj]
Phytomenadione 10mg per milliliter, injection ampoule-vial (Vit K) [B02BA01inj] DH,PH,RH
Phytomenadione 10mg per tablet, oral ingestion tablet-capsule (Vit K) [B02BA01or] RH

B03- ANTIANEMIC PREPARATIONS

Version of 15 December 2007
B03A- IRON PREPARATIONS
Ferrous sulfate (strength in Fe equivalent) 125mg per five milliliter, oral ingestion liquid [B03AA07or] BHC*,CHC,DH
Ferrous sulfate (strength in Fe equivalent) 65mg per tablet, oral ingestion tablet-capsule [B03AA07or] HP,BHC,CHC,DH DH,PH,RH
Ferrous sulfate (strength in Fe equivalent) 60mg + Folic acid 0.4mg per tablet, oral ingestion tablet-capsule [B03AD03] BHC*,CHC,DH DH,PH,RH
Iron dextran 50mg per milliliter, in 2ml ampoule, injection ampoule-vial [B03AC06inj] RH

B03B- VITAMIN B12 AND FOLIC ACID
Folic Acid 1mg per tablet, oral ingestion tablet-capsule (Vit B9) [B03BB01or] DH,PH,RH
Folic acid 5mg per tablet, oral ingestion tablet-capsule (Vit B9) [B03BB01or] BHC,CHC,DH DH,PH,RH
Hydroxocobalamine 0.5mg per milliliter, in 1ml ampoule, injection ampoule-vial (Vit B12) [B03BA03inj] PH,PH,RH
Hydroxocobalamine 1mg per milliliter, in 1ml ampoule, injection ampoule-vial (Vit B12) [B03BA03inj] PH,PH,RH

B05- BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B05A- BLOOD AND RELATED PRODUCTS
Dextran 70 6% injection solution [B05AA05] RH

B05B- I.V. SOLUTIONS
Glucose 4% + Sodium chloride 0.18% in 500ml bottle, injection solution [B05BB02] BHC,CHC,DH PH,PH,RH
Glucose 50% injection solution [B05BA03] BHC,CHC,DH PH,PH,RH
Mannitol 10% in 100ml bottle, injection solution [B05BC01] BHC,CHC,DH DH,PH,RH
Ringer lactate per milliliter, in 1000ml bottle, injection solution (Compound Sodium Lactate Solution) [B05BB02] BHC*,CHC,DH DH,PH,RH
Sodium Chloride 0.9%, in 1000ml bottle, injection solution [B05BB01] BHC*,CHC,DH DH,PH,RH

B05C- IRRIGATING SOLUTIONS
Glucose 10% in 500ml bottle, injection solution [B05CX01] BHC,CHC,DH DH,PH,RH
Glucose 5% in 500ml bottle, injection solution [B05CX01] BHC,CHC,DH DH,PH,RH
Sodium bicarbonate 8.4% in 10ml vial, injection ampoule-vial [B05CB04] CHC,DH RH

B05X- I.V. SOLUTION ADDITIVES
Potassium chloride 11.2% in 20ml ampoule, injection solution [B05XA01] CHC,DH RH

C- CARDIOVASCULAR SYSTEM

Version of 15 December 2007
C01- CARDIAC THERAPY
C01A- CARDIAC GLYCOSIDES
Digoxin 0.25mg per milliliter, in 2ml ampoule, injection solution [C01AA05inj] DH,PH,RH
Digoxin 0.25mg per tablet, oral ingestion tablet-capsule [C01AA05or] DH,PH,RH

C01B- ANTIARRHYTHMIC, CLASS I AND III
Lidocaine 20mg per milliliter, in 5ml ampoule, injection ampoule-vial [C01BB01inj] RH
Procainamide 100mg per milliliter, in 10ml ampoule, injection solution [C01BA02inj] RH
Procainamide 250mg per tablet, oral ingestion tablet-capsule [C01BA02or] RH

C01C- CARDIAC STIMULANTS EXCL. CARDIAC GLYCOSIDES
Dopamine 40mg per milliliter, in 5ml vial, injection solution [C01CA04inj] BHCH,CHC,DH DH,PH,RH
Epinephrine 0.1% in 1ml ampoule, injection ampoule-vial (Adrenaline) [C01CA24inj] BHC*,CHC,DH RH

C01D- VASODILATORS USED IN CARDIAC DISEASES
Glyceryl trinitrate 0.5mg per tablet, sublingual tablet-capsule (Nitroglycerine) [C01DA02or] RH
Isosorbide dinitrate 10mg per tablet, sublingual tablet-capsule [C01DA08or] DH,PH,RH
Isosorbide dinitrate 20mg per tablet, sublingual tablet-capsule [C01DA08or] DH,PH,RH
Isosorbide dinitrate 5mg per tablet, sublingual tablet-capsule [C01DA08or] DH,PH,RH

C02- ANTIHYPERTENSIVES
C02A- ANTIADRENERGIC AGENTS, CENTRALLY ACTING
Methyldopa 250mg per tablet, oral ingestion tablet-capsule [C02AB01or] BHC,CHC,DH DH,PH,RH

C02D- ARTERIOVASCULAR SMOOTH MUSCLE, AGENTS ACTING ON
Hydralazine 20mg per milliliter, injection ampoule-vial [C02DB01inj] DH,PH,RH
Hydralazine 25mg per tablet, oral ingestion tablet-capsule [C02DB02] RH
Hydralazine 50mg per tablet, oral ingestion tablet-capsule [C02DB02] RH

C03- DIURETICS
C03A- LOW-CEILING DIURETICS, THIAZIDES
Hydrochlorothiazide 25mg per tablet, oral ingestion tablet-capsule [C03AA03or] DH,PH,RH
Hydrochlorothiazide 50mg per tablet, oral ingestion tablet-capsule [C03AA03or] BHC,CHC,DH DH,PH,RH

C03C- HIGH-CEILING DIURETICS
Furosemide 10mg per milliliter, in 2ml ampoule, injection solution [C03CA01inj] DH,PH,RH
Furosemide 40mg per tablet, oral ingestion tablet-capsule [C03CA01or]

C03D- POTASSIUM-SPARING AGENTS
Spironolactone 25mg per tablet, oral ingestion tablet-capsule [C03DA01or]

C07- BETA BLOCKING AGENTS
C07A- BETA BLOCKING AGENTS
Atenolol 100mg per tablet, oral ingestion tablet-capsule [C07AB03or] BHC*,CHC,DH RH
Atenolol 50mg per tablet, oral ingestion tablet-capsule [C07AB03or] BHC*,CHC,DH RH
Esmolol 10mg per milliliter, in 10ml ampoule, injection solution [C07AB09inj] BHC*,CHC,DH RH
Esmolol 250mg per milliliter, in 10ml ampoule, injection solution [C07AB09inj] BHC*,CHC,DH RH
Propranolol 10mg per tablet, oral ingestion tablet-capsule [C07AA05or] DH,PH,RH
Propranolol 40mg per tablet, oral ingestion tablet-capsule [C07AA05or] DH,PH,RH

C08- CALCIUM CHANNEL BLOCKERS
C08C- SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS
Amlodipine 5mg per tablet, oral ingestion tablet-capsule [C08CA01or] BHC*,CHC,DH DH,PH,RH
Nifedipine slow release 10mg per tablet, oral ingestion tablet-capsule [C08CA05or] BHC*,CHC,DH DH,PH,RH
Nifedipine slow release 20mg per tablet, oral ingestion tablet-capsule [C08CA05or] BHC*,CHC,DH DH,PH,RH

C08D- SELECTIVE CALCIUM CHANNEL BLOCKERS WITH DIRECT CARDIAC EFFECTS
Verapamil 2.5mg per milliliter, in 2ml ampoule, injection ampoule-vial [C08DA01inj] BHC*,CHC,DH RH
Verapamil 40mg per tablet, oral ingestion tablet-capsule [C08DA01or] BHC*,CHC,DH RH
Verapamil 80mg per tablet, oral ingestion tablet-capsule [C08DA01or] BHC*,CHC,DH RH

C09- AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM
C09A- ACE INHIBITORS, PLAIN
Captopril 25mg per tablet, oral ingestion tablet-capsule [C09AA01or] BHC*,CHC,DH RH
Enalapril 10mg per tablet, oral ingestion tablet-capsule [C09AA02or] BHC*,CHC,DH RH

C10- LIPID MODIFYING AGENTS
Clofibrate 500mg per tablet, oral ingestion tablet-capsule [C10AB01or] BHC*,CHC,DH RH
Colestyramine 4gr per sachet, oral ingestion suspension-syrup-liquid [C10AC01or] BHC*,CHC,DH RH
Simvastatin 20mg per tablet, oral ingestion tablet-capsule [C10AA01or] BHC*,CHC,DH RH

Version of 15 December 2007
D- DERMATOLOGICALS

D01- ANTIFUNGALS FOR DERMATOLOGICAL USE
D01A- ANTIFUNGALS FOR TOPICAL USE
Ketoconazole 2% in 15gr tube, topical cream-ointment-gel [D01AC08] DH,PH,RH
Ketoconazole 2% topical shampoo [D01AC08] HP,BHC,CHC,DH
Methylrosaniline 0.5% in 10ml bottle, topical solution (Gentian Violet) [D01AE02] HP,BHC,CHC,DH DH,PH,RH
Methylrosaniline 1% in 10ml bottle, topical solution (Gentian Violet) [D01AE02] HP,BHC,CHC,DH DH,PH,RH
Methylrosaniline 25gr per bottle, topical crystals (Gentian Violet) [D01AE02] HP,BHC,CHC,DH DH,PH,RH
Nystatin 100000IU per gram, in 25gr tube, topical cream-ointment-gel [D01AA01] BHC,CHC,DH DH,PH,RH
Salicylic acid 5% topical solution [D01AE12] DH, PH, RH
Terbinafine 1% in 30gr tube, topical cream-ointment-gel [D01AE15] DH,PH,RH

D01B- ANTIFUNGALS FOR SYSTEMIC USE
Griseofulvin 125mg per tablet, oral ingestion tablet-capsule [D01BA01or] PH,RH
Griseofulvin 250mg per tablet, oral ingestion tablet-capsule [D01BA01or] PH,RH
Griseofulvin 500mg per tablet, oral ingestion tablet-capsule [D01BA01or] PH,RH
Terbinafine 125mg per tablet, oral ingestion tablet-capsule [D01BA02or] DH,PH,RH

D02- EMOLLIENTS AND PROTECTIVES
D02A- EMOLLIENTS AND PROTECTIVES
Zinc oxide 10% in 20gr tube, topical cream-ointment-gel [D02AB01] DH,PH,RH
Zinc oxide 20% in 20gr tube, topical cream-ointment-gel [D02AB01] DH,PH,RH

D04- ANTIPRURITICS, INCL. ANTIHISTAMINES, ANESTHETICS, ETC.
Calamine (ZnO + Fe2O3) 8% in 30gr tube, topical cream-ointment-gel [D04AX01] DH,PH,RH
Calamine (ZnO + Fe2O3) 8% in 60ml bottle, topical lotion [D04AX01] BHC,CHC,DH DH,PH,RH
Lidocaine 2% in 15gr tube, topical cream-ointment-gel [D04AB04] BHC,CHC,DH DH,PH,RH
Lidocaine 4% topical cream-ointment-gel [D04AB04] BHC,CHC,DH DH,PH,RH

D05- ANTIPSORIATICS
Coal tar 5% in 100gr bottle, topical lotion [D05AA01] RH

Version of 15 December 2007
D06- ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE
D06A- ANTIBIOTICS FOR TOPICAL USE
Mupirocin 2% in 10gr tube, topical cream-ointment-gel [D06AX09]  
Neomycin 5mg + Bacitracin 500IU per gram, in 15gr tube, topical cream-ointment-gel [D06AX51]  

D06B- CHEMOTHERAPEUTICS FOR TOPICAL USE
Metronidazole 0.75% in 15gel tube, topical cream-ointment-gel [D06BX01]  
Silver sulfadiazine 1% in 20gr tube, topical cream-ointment-gel [D06BA01]  

D07- CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS
D07A- CORTICOSTEROIDS, PLAIN
Hydrocortison acetate 1% in 15gr tube, topical cream-ointment-gel [D07AA02]  

D07C- CORTICOSTEROIDS, COMBINATIONS WITH ANTIBIOTICS
Betamethasone 0.1% + Neomycine 0.5% in 15gr tube, topical cream-ointment-gel [D07CC01]  

D08- ANTISEPTICS AND DISINFECTANTS
Boric acid glycerine 5%topical solution [D08AD01]  
Chlorhexidine digluconate 5%topical solution [D08AC02]  
Chlorhexidine gluconate 1.5% + Cetrimide 15%topical solution [D08AC52]  
Hydrogen peroxide 6%topical solution [D08AX01]  
Potassium permanganate 0.01%topical solution [D08AX06]  
Povidone-iodine 10%topical solution [D08AG02]  
Sodium hypochlorite 0.5%topical solution [D08AX07]  

D10- ANTI-ACNE PREPARATIONS
Benzoyl Peroxide 5%topical cream-ointment-gel [D10AE01]  
Benzoyl Peroxide 5%topical lotion [D10AE01]  
Sulfur 2% + Salicylic acid 1%topical cream-ointment-gel [D10AB02]  

G- GENITO URINARY SYSTEM AND SEX HORMONES
G01- GYNECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS  

Version of 15 December 2007
Furazolidone 100mg per tablet, oral ingestion tablet-capsule [G01AX06] RH
Furazolidone 125mg per five milliliter, oral ingestion suspension-syrup-liquid [G01AX06] RH
Nystatin 100000iu per tablet, vaginal tablet-capsule [G01AA01vg] BHC,CHC,DH DH,PH,RH

**G02- OTHER GYNECOLOGICALS**

**G02A- OXYTOCICS**
Ergometrine maleate 0.2mg per milliliter, injection ampoule-vial [G02AB03inj] CHC,DH DH,PH,RH
Ergometrine maleate 0.2mg per tablet, oral ingestion tablet-capsule [G02AB03or] BHC*,CHC,DH DH,PH,RH
Methylergometrine maleate 0.2mg per milliliter, injection ampoule-vial [G02AB01inj] BHC,CHC,DH DH,PH,RH

**G02B- CONTRACEPTIVES FOR TOPICAL USE**
Condom w/wo nonoxinol 1pce per piece, topical piece [G02BX01] HP,BHC,CHC,DH DH,PH,RH
Intrauterine device with copper 1pce per piece, vaginal intra uterine device [G02BA02] BHC*,CHC,DH DH,PH,RH

**G02C- OTHER GYNECOLOGICALS**
Nifedipine 10mg per tablet, oral ingestion tablet-capsule [G02CA04or] CHC,DH DH,PH,RH
Nifedipine 20mg per tablet, oral ingestion tablet-capsule [G02CA04or] CHC,DH DH,PH,RH

**G03- SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM**

**G03A- HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE**
Ethinylestradiol 0.035mg + Norethisterone 1mg per tablet, oral ingestion tablet-capsule [G03AA05] HP,BHC,CHC,DH DH,PH,RH
Ethinylestradiol 0.03mg + Levonorgestrel 0.15mg per tablet, oral ingestion tablet-capsule [G03AA07] HP,BHC,CHC,DH DH,PH,RH
Ethinylestradiol 0.03mg + Levonorgestrel 0.15mg per tablet, oral ingestion tablet-capsule [G03AA07] HP,BHC,CHC,DH DH,PH,RH
Ethinylestradiol 0.03mg + Norgestrel 0.3mg per tablet, oral ingestion tablet-capsule [G03AA06] HP,BHC,CHC,DH DH,PH,RH
Ethinylestradiol 0.05mg + Levonorgestrel 0.25mg per tablet, oral ingestion tablet-capsule [G03AA07] HP,BHC,CHC,DH DH,PH,RH
Medroxyprogesterone acetate Depot 150mg per milliliter, in 1ml vial, injection solution [G03AC06inj] BHC*,CHC,DH DH,PH,RH
Norgestrel 0.075mg per tablet, oral ingestion tablet-capsule [G03AC10] HP,BHC,CHC,DH DH,PH,RH

**G03C- ESTROGENS**
Ethinylestradiol 0.01mg per tablet, oral ingestion tablet-capsule [G03CA01or] HP,BHC,CHC,DH DH,PH,RH
Ethinylestradiol 0.05mg per tablet, oral ingestion tablet-capsule [G03CA01or] HP,BHC,CHC,DH DH,PH,RH

**G03G- GONADOTROPINS AND OTHER OVULATION STIMULANTS**
Clomifene 50mg per tablet, oral ingestion tablet-capsule [G03GB02or] RH

Version of 15 December 2007
H- SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS

H01- PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H01B- POSTERIOR PITUITARY LOBE HORMONES
Oxytocine 10IU per milliliter, in 1ml ampoule, injection solution [H01BB02inj] CHC,DH DH,PH,RH

H02- CORTICOSTEROIDS FOR SYSTEMIC USE
Hydrocortisone sodium succinate 100mg per vial, injection ampoule-vial [H02AB09inj] BHC,CHC,DH DH,PH,RH
Prednisolone 5mg per tablet, oral ingestion tablet-capsule [H02AB06or] DH,PH,RH

H03- THYROID THERAPY
Carbimazole 5mg per tablet, oral ingestion tablet-capsule [H03BB01or] RH
Iodine (oil) 480mg per milliliter, in 1ml ampoule, oral ingestion solution [H03CA20] RH
Iodine 200mg per capsule, oral ingestion tablet-capsule [H03CA20] BHC,CHC,DH RH
Iodine 480mg per milliliter, in 0.5ml ampoule, injection ampoule-vial [H03CA20] RH
Iodine 480mg per milliliter, in 0.5ml ampoule, oral ingestion tablet-capsule [H03CA20] BHC,CHC,DH RH
Iodine 540mg per milliliter, in 0.57ml bottle, oral ingestion solution [H03CA20] RH
Levothyroxine 0.05mg per tablet, oral ingestion tablet-capsule [H03AA01or] RH
Levothyroxine 0.1mg per tablet, oral ingestion tablet-capsule [H03AA01or] RH

J- ANTIINFECTIVES FOR SYSTEMIC USE

J01- ANTIBACTERIALS FOR SYSTEMIC USE
J01A- TETRACYCLINES
Doxycycline 100mg per capsule, oral ingestion tablet-capsule [J01AA02or] BHC*,CHC,DH DH,PH,RH

J01B- AMPHENICOLS
Chloramphenicol 125mg per five milliliter, in 100ml bottle, oral ingestion suspension-syrup-liquid [J01BA01or] BHC*,CHC,DH DH,PH,RH
Chloramphenicol 1gr per vial, injection powder [J01BA01or] BHC*,CHC,DH DH,PH,RH
Chloramphenicol 250mg per capsule, oral ingestion tablet-capsule [J01BA01or] BHC*,CHC,DH DH,PH,RH
Chloramphenicol 500mg per vial, injection powder [J01BA01inj] BHC*,CHC,DH DH,PH,RH

Version of 15 December 2007
J01C- BETA-LACTAM ANTIBACTERIALS, PENICILLINS

Amoxicillin 125mg + Clavulanic acid 31.25mg per five milliliter, in 60ml bottle, oral ingestion suspension-syrup-liquid (Co-amoxiclav) [J01CR02or]

Amoxicillin 125mg per five milliliter, in 60ml bottle, oral ingestion suspension-syrup-liquid [J01CA04or]

Amoxicillin 250mg per five milliliter, in 60ml bottle, oral ingestion suspension-syrup-liquid [J01CA04or]

Amoxicillin 250mg per tablet, oral ingestion tablet-capsule [J01CA04or]

Amoxicillin 500mg + Clavulanic acid 125mg per tablet, oral ingestion tablet-capsule (Co-amoxiclav) [J01CR02or]

Amoxicillin 500mg per tablet, oral ingestion tablet-capsule [J01CA04or]

Ampicillin 1gr per vial, injection ampoule-vial [J01CA01inj]

Ampicillin 500mg per vial, injection ampoule-vial [J01CA01inj]

Cloxacillin 250mg per capsule, oral ingestion tablet-capsule [J01CF02or]

Cloxacillin 500mg per capsule, oral ingestion tablet-capsule [J01CF02or]

Cloxacillin 500mg per vial, injection ampoule-vial [J01CF02inj]

Penicillin Benzyl 0.5MU + Penicillin procaine 1.5MU per vial, injection ampoule-vial [J01CE09inj]

Penicillin Benzyl 1MU + Penicillin procaine 3MU per vial, injection ampoule-vial [J01CE09inj]

Penicillin Benzyl 2MU + Penicillin procaine 6MU per vial, injection ampoule-vial [J01CE09inj]

Penicillin Benzyl 5MU per vial, injection ampoule-vial (Peni G) [J01CE01inj]

Penicillin Benzyl Benzathine 1.2MU per vial, injection ampoule-vial [J01CE08inj]

Penicillin Benzyl Benzathine 2.4MU per vial, injection ampoule-vial [J01CE08inj]

Penicillin Benzyl Procaine 2MU per vial, injection ampoule-vial [J01CE09inj]

Penicillin V(Phenoxy methyl Penicillin) 250mg per five milliliter, in 100ml bottle, oral ingestion suspension-syrup-liquid [J01CE02or]

Penicillin V(Phenoxy methyl Penicillin) 500mg per tablet, oral ingestion tablet-capsule [J01CE02or]

Penicillin V(Phenoxy methyl Penicillin) 500mg per vial, injection ampoule-vial [J01CE02inj]

J01D- OTHER BETA-LACTAM ANTIBACTERIALS

Ceftriaxone 1gr per vial, injection ampoule-vial [J01DD04inj]

Ceftriaxone 500mg per vial, injection ampoule-vial [J01DD04inj]

J01E- SULFONAMIDES AND TRIMETHOPRIM

Sulfamethoxazole 100mg + Trimethoprim 20mg per tablet, oral ingestion tablet-capsule (Cotrimoxazole) [J01EE01]

Sulfamethoxazole 200mg + Trimethoprim 40mg per five milliliter, in 50ml bottle, oral ingestion suspension-syrup-liquid (Cotrimoxazole) [J01EE01]

Sulfamethoxazole 400mg + Trimethoprim 80mg per tablet, oral ingestion tablet-capsule (Cotrimoxazole) [J01EE01]

J01F- MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS

Erythromycin (Base) 125mg per five milliliter, oral ingestion suspension-syrup-liquid [J01FA01or]

Erythromycin (Base) 200mg per five milliliter, oral ingestion suspension-syrup-liquid [J01FA01or]

Erythromycin (Base) 200mg per tablet, oral ingestion tablet-capsule [J01FA01or]

Erythromycin (Base) 400mg per tablet, oral ingestion tablet-capsule [J01FA01or]

Version of 15 December 2007
Erythromycin stearate 250mg per tablet, oral ingestion tablet-capsule [J01FA01or]
Erythromycin stearate 500mg per tablet, oral ingestion tablet-capsule [J01FA01or]

**J01G- AMINOGLYCOSIDE ANTIBACTERIALS**
Gentamicin 10mg per milliliter, in 2ml ampoule, injection solution [J01GB03inj] DH,PH,RH
Gentamicin 20mg per milliliter, in 2ml ampoule, injection solution [J01GB03inj] BHC*,CHC,DH DH,PH,RH
Gentamicin 40mg per milliliter, in 2ml ampoule, injection solution [J01GB03inj] BHC*,CHC,DH DH,PH,RH
Streptomycin 1gr per vial, injection ampoule-vial [J01GA01inj] DH,PH,RH

**J01M- QUINOLONE ANTIBACTERIALS**
Ciprofloxacin 250mg per tablet, oral ingestion tablet-capsule [J01MA02or] PH,RH
Ciprofloxacin 2mg per milliliter, in 50ml ampoule, injection solution [J01MA02inj] PH,RH
Ciprofloxacin 500mg per tablet, oral ingestion tablet-capsule [J01MA02or] PH,RH
Nalidixic Acid 150mg per five milliliter, in 60ml bottle, oral ingestion suspension-syrup-liquid [J01MB02or] BHC,CHC,DH DH,PH,RH
Nalidixic Acid 250mg per five milliliter, in 60ml bottle, oral ingestion suspension-syrup-liquid [J01MB02or] BHC,CHC,DH DH,PH,RH
Nalidixic Acid 250mg per tablet, oral ingestion tablet-capsule [J01MB02or] BHC,CHC,DH DH,PH,RH
Nalidixic Acid 500mg per tablet, oral ingestion tablet-capsule [J01MB02or] BHC,CHC,DH DH,PH,RH

**J01X- OTHER ANTIBACTERIALS**
Metronidazole 5mg per milliliter, in 100ml bottle, injection solution [J01XD01inj] CHC,DH DH,PH,RH
Nitrofurantoin 100mg per tablet, oral ingestion tablet-capsule [J01XE01or] BHC,CHC,DH DH,PH,RH

**J02- ANTIMYCOCOTICS FOR SYSTEMIC USE**
Ketoconazole 200mg per tablet, oral ingestion tablet-capsule [J02AB02or] DH,PH,RH

**J04- ANTIMYCOBACTERIALS**
**J04A- DRUGS FOR TREATMENT OF TUBERCULOSIS**
Ethambutol 400mg + Isoniazid 75mg per tablet, oral ingestion tablet-capsule (EH) [J04AM03] DH,PH,RH
Ethambutol 400mg per tablet, oral ingestion tablet-capsule (E) [J04AK02or] BHC,CHC,DH DH,PH,RH
Isoniazid 100mg per tablet, oral ingestion tablet-capsule (H) [J04AC01or] BHC,CHC,DH DH,PH,RH
Isoniazid 300mg per tablet, oral ingestion tablet-capsule [J04AC01or] BHC,CHC,DH DH,PH,RH
Pyrazinamide 150mg per tablet, oral ingestion tablet-capsule (Z) [J04AK01or] BHC,CHC,DH DH,PH,RH
Pyrazinamide 400mg per tablet, oral ingestion tablet-capsule (Z) [J04AK01or] BHC,CHC,DH DH,PH,RH
Pyrazinamide 500mg per tablet, oral ingestion tablet-capsule (Z) [J04AK01or] BHC,CHC,DH DH,PH,RH
Rifampicin 150mg + Isoniazid 75mg + Ethambutol 275mg per tablet, oral ingestion tablet-capsule (RHE) [J04AM07] DH,PH,RH
Rifampicin 150mg + Isoniazid 75mg + Pyrazinamide 400mg + Ethambutol 275mg per tablet, oral ingestion tablet-capsule (RHZE) [J04AM06] DH,PH,RH

Version of 15 December 2007
Rifampicin 150mg + Isoniazid 75mg per tablet, oral ingestion tablet-capsule (RH) [J04AM02] DH,PH,RH
Rifampicin 60mg + Isoniazid 30mg + Pyrazinamide 150mg per tablet, oral ingestion tablet-capsule (RHZ) [J04AM05] DH,PH,RH
Rifampicin 60mg + Isoniazid 30mg per tablet, oral ingestion tablet-capsule (RH) [J04AM02] DH,PH,RH
Streptomycin 1 gr per vial, injection ampoule-vial (S) [J04AB31inj] DH,PH,RH

**J04B- DRUGS FOR TREATMENT OF LEPROSIA**
Clofazimine 100mg per capsule, oral ingestion tablet-capsule [J04BA01or]
Clofazimine 50mg per capsule, oral ingestion tablet-capsule [J04BA01or]
Dapsone 100mg per tablet, oral ingestion tablet-capsule [J04BA02or]
Dapsone 25mg per tablet, oral ingestion tablet-capsule [J04BA02or]
Dapsone 50mg per tablet, oral ingestion tablet-capsule [J04BA02or]
Rifampicin 300mg + Dapsone 50mg + Clofazimine 50mg per tablet, oral ingestion tablet-capsule (R) [J04BM01]

**J05- ANTIVIRALS FOR SYSTEMIC USE**
Abacavir 100mg per five milliliter, oral ingestion solution (ABC) [J05AF06or]
Abacavir 300mg per tablet, oral ingestion tablet-capsule (ABC) [J05AF06or]
Atazanavir 300mg + Ritonavir 100mg per tablet, oral ingestion tablet-capsule (ATVRTV) [J05AR12]
Emtricitabine 200mg + Tenofovir 300mg per tablet, oral ingestion tablet-capsule (FTCTDF) [J05AR03]
Fosamprenavir 700mg + Ritonavir per tablet, oral ingestion tablet-capsule (FPVRTV) [J05AR13]
Indinavir 200mg per capsule, oral ingestion tablet-capsule (IDV) [J05AE02or]
Indinavir 333mg per capsule, oral ingestion tablet-capsule (IDV) [J05AE02or]
Indinavir 400mg per capsule, oral ingestion tablet-capsule (IDV) [J05AE02or]
Indinavir 800mg + Ritonavir per tablet, oral ingestion tablet-capsule (IDVRTV) [J05AR11]
Lopinavir 200mg + Ritonavir 50mg per tablet, oral ingestion tablet-capsule (LPVRTV) [J05AR07]
Nelfinavir 200mg per five milliliter, oral ingestion suspension-syrup-liquid (NFV) [J05AE04or]
Nelfinavir 250mg per tablet, oral ingestion tablet-capsule (NFV) [J05AE04or]
Nelfinavir 50mg per pack, oral ingestion powder (NFV) [J05AE04or]
Nelfinavir 625mg per tablet, oral ingestion tablet-capsule (NFV) [J05AE04or]
Saquinavir 200mg + Ritonavir 500mg per tablet, oral ingestion tablet-capsule (SQVRTV) [J05AR08]
Stavudine 10mg + Lamivudine 40mg per five milliliter, oral ingestion solution (d4T3TC) [J05AR09]
Stavudine 30mg + Lamivudine 150mg per tablet, oral ingestion tablet-capsule (d4T3TC) [J05AR09]
Stavudine 40mg + Lamivudine 150mg + Nevirapine 200mg per tablet, oral ingestion tablet-capsule (d4T3TCNVP) [J05AR10]
Stavudine 40mg + Lamivudine 150mg per tablet, oral ingestion tablet-capsule (d4T3TC) [J05AR09]
Zidovudine 100mg per capsule, oral ingestion tablet-capsule (AZT) [J05AF01or]
Zidovudine 250mg per capsule, oral ingestion tablet-capsule (AZT) [J05AF01or]
Zidovudine 250mg per tablet, oral ingestion tablet-capsule (AZT) [J05AF01or]
Zidovudine 300mg per tablet, oral ingestion tablet-capsule (AZT) [J05AF01or]
Zidovudine 50mg per five milliliter, oral ingestion suspension-syrup-liquid (AZT) [J05AF01or]

**J06- IMMUNE SERA AND IMMUNOGLOBULINS**

Version of 15 December 2007
J06A- IMMUNE SERA
Antitetanus Immunoglobulin 1500IU per milliliter, in 1ml ampoule, injection ampoule-vial [J06AA02] DH,PH,RH
Antitetanus Immunoglobulin 3000IU per milliliter, in 1ml ampoule, injection ampoule-vial [J06AA02] DH,PH,RH
Antitetanus Immunoglobulin 500IU per milliliter, in 1ml ampoule, injection ampoule-vial [J06AA02] DH,PH,RH
Rabies antitoxin 150mg per milliliter, injection ampoule-vial [J06AA06] DH,PH,RH

J06B- IMMUNOGLOBULINS
Anti-D immunoglobulin (human) 250mcg per dose, in 1dose vial, injection ampoule-vial [J06BB01] PH,RH
Diphtheria antitoxin 10000IU per vial, injection ampoule-vial [J06BB10] PH,RH
Diphtheria antitoxin 20000IU per vial, injection ampoule-vial [J06BB10] PH,RH
Pertussis antitoxin per vial, injection ampoule-vial [J06BB13] PH,RH

J07- VACCINES
J07A- BACTERIAL VACCINES
Diphtheria, pertussis, tetanus vaccine 20dose per vial, injection ampoule-vial [J07AF30] BHC,CHC,DH DH,PH,RH
Tetanus toxoid vaccine 20dose per vial, injection ampoule-vial [J07AM01] BHC,CHC,DH DH,PH,RH
Tuberculosis vaccine 20dose per vial, injection ampoule-vial [J07AN01] BHC,CHC,DH DH,PH,RH
Tuberculosis vaccine diluent 20dose per vial, injection ampoule-vial [J07AN01] BHC,CHC,DH DH,PH,RH

J07B- VIRAL VACCINES
Measles diluent 10dose per vial, injection ampoule-vial [J07BD01] BHC,CHC,DH DH,PH,RH
Measles vaccine 10dose per vial, injection ampoule-vial [J07BD01] BHC,CHC,DH DH,PH,RH
Mumps vaccine per vial, injection ampoule-vial [J07BE01] BHC,CHC,DH DH,PH,RH
Oral polio vaccine-monovalent 20dose per vial, injection ampoule-vial (OPV-M) [J07BF01] BHC,CHC,DH DH,PH,RH
Oral polio vaccine-tetravalent 20dose per vial, injection ampoule-vial (OPV-T) [J07BF02] BHC,CHC,DH DH,PH,RH

J07C- BACTERIAL AND VIRAL VACCINES, COMBINED
Diphtheria, pertussis, tetanus-Hepatitis B vaccine 10dose per vial, injection ampoule-vial [J07CA52] BHC,CHC,DH DH,PH,RH

L- ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01- ANTINEOPLASTIC AGENTS
Fluorouracil 5% topical cream-ointment-gel [L01BC02] RH

Version of 15 December 2007
L02- ENDOCRINE THERAPY
Ethynylestradiol 0.05mg per tablet, oral ingestion tablet-capsule [L02AA03or] RH

M- MUSCULO-SKELETAL SYSTEM

M01- ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
M01A- ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Ibuprofen 200mg per tablet, oral ingestion tablet-capsule [M01AE01or] BHC,CHC,DH DH,PH,RH
Ibuprofen 400mg per tablet, oral ingestion tablet-capsule [M01AE01or] DH,PH,RH

M01C- SPECIFIC ANTIRHEUMATIC AGENTS
Methotrexate 2.5mg per tablet, oral ingestion tablet-capsule [M01CX01or]
Penicillamine 125mg per tablet, oral ingestion tablet-capsule [M01CC01or]
Penicillamine 250mg per tablet, oral ingestion tablet-capsule [M01CC01or]
Sulfasalazine 500mg per tablet, oral ingestion tablet-capsule [M01CX02or]

M03- MUSCLE RELAXANTS
Alcuronium 5mg per milliliter, in 2ml ampoule, injection solution [M03AA01] RH
Suxamethonium 50mg per milliliter, in 2ml ampoule, injection solution [M03AB01] DH,PH,RH

M04- ANTIGOUT PREPARATIONS
Allopurinol 100mg per tablet, oral ingestion tablet-capsule [M04AA01or] RH
Colchicine 0.5mg per tablet, oral ingestion tablet-capsule [M04AC01or] RH

N- NERVOUS SYSTEM

N01- ANESTHETICS
N01A- ANESTHETICS, GENERAL
Halothane 250ml per milliliter, in 250ml bottle, inhalation solution [N01AB01] RH
Ketamin 50mg per milliliter, in 10ml vial, injection solution [N01AX03] CHC,DH DH,PH,RH

Version of 15 December 2007
<table>
<thead>
<tr>
<th>N01B- ANESTHETICS, LOCAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thiopental sodium 1gr per vial, injection powder [N01AF03]</td>
</tr>
<tr>
<td>Thiopental sodium 500mg per vial, injection powder [N01AF03]</td>
</tr>
<tr>
<td>Thiopental sodium 500mg per vial, injection powder [N01AF03]</td>
</tr>
</tbody>
</table>

**Bupivacaine 0.25% in 10ml ampoule, injection solution [N01BB01]**

**Bupivacaine 0.5% in 10ml ampoule, injection solution [N01BB01]**

**Lidocaine 1% + Adrenalin 0.0005% injection solution [N01BB52]**

**Lidocaine 1% injection ampoule-vial [N01BB02]**

**Lidocaine 2% + Adrenalin 0.0005% injection solution [N01BB52]**

**Lidocaine 2% in 2ml ampoule, injection solution [N01BB02]**

**Lidocaine 2% topical cream-ointment-gel [N01BB02]**

**Lidocaine 4% topical cream-ointment-gel [N01BB02]**

**Lidocaine 5% + Glucose 7.5% injection ampoule-vial (Lidocaine Spinal) [N01BB52]**

**Lidocaine dental 1% + Adrenalin 0.00125% injection solution [N01BB52]**

**Lidocaine dental 2% + Adrenalin 0.00125% injection solution [N01BB52]**

**N02- ANALGESICS**

**N02A- OPIOIDS**

**Morphine Sulphate 10mg per milliliter, in 2ml ampoule, injection solution [N02AA01inj]**

**Pethidine 100mg per tablet, oral ingestion tablet-capsule [N02AB02or]**

**Pethidine 50mg per milliliter, injection ampoule-vial [N02AB02inj]**

**Pethidine 50mg per tablet, oral ingestion tablet-capsule [N02AB02or]**

**N02B- OTHER ANALGESICS AND ANTIPYRETICS**

**Acetylsalicylic acid 100mg per tablet, oral ingestion tablet-capsule (Aspirin) (ASA) [N02BA01or]**

**Acetylsalicylic acid 325mg per tablet, oral ingestion tablet-capsule (Aspirin) (ASA) [N02BA01or]**

**Acetylsalicylic acid 500mg per tablet, oral ingestion tablet-capsule (Aspirin) (ASA) [N02BA01or]**

**Paracetamol 100mg per milliliter, in 15ml bottle, oral ingestion drop (Acetaminophen) [N02BE01or]**

**Paracetamol 100mg per tablet, oral ingestion tablet-capsule (Acetaminophen) [N02BE01or]**

**Paracetamol 120mg per five milliliter, in 60ml bottle, oral ingestion suspension-syrup-liquid (Acetaminophen) [N02BE01or]**

**Paracetamol 325mg per tablet, oral ingestion tablet-capsule (Acetaminophen) [N02BE01or]**

**Paracetamol 500mg per tablet, oral ingestion tablet-capsule (Acetaminophen) [N02BE01or]**

**N02C- ANTIMIGRAINE PREPARATIONS**

**Ergotamine 1mg per tablet, oral ingestion tablet-capsule [N02CA02or]**

**N03- ANTIEPILEPTICS**

**N03A- ANTIEPILEPTICS**

---

*Version of 15 December 2007*
Carbamazepine 100mg per tablet, oral ingestion tablet-capsule [N03AF01or] RH
Carbamazepine 200mg per tablet, oral ingestion tablet-capsule [N03AF01or] BHC,CHC,DH RH
Ethosuximide 250mg per capsule, oral ingestion tablet-capsule [N03AD01or] RH
Ethosuximide 250mg per five milliliter, oral ingestion milliliter [N03AD01or] RH
Magnesium sulfate 500mg per milliliter, in 10ml ampoule, injection solution [N03AX31] CHC,DH DH,PH,RH
Phenobarbital 100mg per milliliter, in 2ml milliliter, injection ampoule-vial [N03AA02inj] BHC*,CHC,DH DH,PH,RH
Phenobarbital 100mg per tablet, oral ingestion tablet-capsule [N03AA02or] BHC*,CHC,DH DH,PH,RH
Phenobarbital 15mg per tablet, oral ingestion tablet-capsule [N03AA02or] BHC*,CHC,DH DH,PH,RH
Phenobarbital 25mg per tablet, oral ingestion tablet-capsule [N03AA02or] BHC*,CHC,DH DH,PH,RH
Phenobarbital 30mg per tablet, oral ingestion tablet-capsule [N03AA02or] BHC*,CHC,DH DH,PH,RH
Phenobarbital 50mg per milliliter, injection ampoule-vial [N03AA02inj] DH,PH,RH
Phenobarbital 50mg per tablet, oral ingestion tablet-capsule [N03AA02or] DH,PH,RH
Valproic acid 200mg per tablet, oral ingestion tablet-capsule [N03AG01or] RH
Valproic Acid 500mg per tablet, oral ingestion tablet-capsule [N03AG01or] RH

N04- ANTI-PARKINSON DRUGS
N04A- ANTICHOLINERGIC AGENTS
Biperiden 2mg per tablet, oral ingestion tablet-capsule [N04AA02or] RH
Biperiden 5mg per milliliter, in 1ml ampoule, injection ampoule-vial [N04AA02inj] RH
Trihexyphenidyl 2mg per tablet, oral ingestion tablet-capsule (Benzhexol) [N04AA01or] RH

N04B- DOPAMINERGIC AGENTS
Bromocriptine (as mesylate) 2.5mg per tablet, oral ingestion tablet-capsule [N04BC01or] RH
Levodopa 100mg + Carbidopa 10mg per tablet, oral ingestion tablet-capsule [N04BA02or] RH
Levodopa 250mg + Carbidopa 25mg per tablet, oral ingestion tablet-capsule [N04BA02or] RH

N05- PSYCHOLEPTICS
N05A- ANTI-PSYCHOTICS
Chlorpromazine 100mg per tablet, oral ingestion tablet-capsule [N05AA01or] DH RH
Chlorpromazine 25mg per five milliliter, oral ingestion solution [N05AA01or] DH RH
Chlorpromazine 25mg per milliliter, in 2ml ampoule, injection solution [N05AA01inj] DH RH
Fluphenazine (oily) 1mg per milliliter, in 1ml ampoule, injection solution [N05AB02inj]
Fluphenazine 1mg per tablet, oral ingestion tablet-capsule [N05AB02or]
Fluphenazine 2.5mg per tablet, oral ingestion tablet-capsule [N05AB02or]
Fluphenazine 5mg per tablet, oral ingestion tablet-capsule [N05AB02or]
Haloperidol 2mg per tablet, oral ingestion tablet-capsule [N05AD01or] DH,PH,RH
Haloperidol 5mg per milliliter, injection ampoule-vial [N05AD01inj] DH,PH,RH
Haloperidol 5mg per tablet, oral ingestion tablet-capsule [N05AD01or] DH,PH,RH
Thioridazine 25mg per tablet, oral ingestion tablet-capsule [N05AC02or] DH,PH,RH

Version of 15 December 2007
N05B- ANXIOLYTICS
Alprazolam 0.5mg per tablet, oral ingestion tablet-capsule [N05BA12or] PH,RH
Diazepam 10mg per tablet, oral ingestion tablet-capsule [N05BA01or] BHC*,CHC,DP,H,P,RH
Diazepam 2mg per tablet, oral ingestion tablet-capsule [N05BA01or] DH,P,RH
Diazepam 5mg per tablet, oral ingestion tablet-capsule [N05BA01or] BHC*,CHC,DP,H,P,RH
Diazepam 5mg per milliliter, in 2ml milliliter, injection solution [N05BA01inj] DH,P,RH

N06- PSYCHOANALEPTICS
N06A- ANTIDEPRESSANTS
Amitriptylline 25mg per tablet, oral ingestion tablet-capsule [N06AA09or] CHC,DP,H,P,RH
Clomipramine 10mg per tablet, oral ingestion tablet-capsule [N06AA04or] BHC,CHC,DP,H,P,RH
Imipramine 50mg per tablet, oral ingestion tablet-capsule [N06AA04or] DH,P,RH
Fluoxetine 20mg per capsule, oral ingestion tablet-capsule [N06AB03or] DH,P,RH
Nortriptyline 10mg per tablet, oral ingestion tablet-capsule [N06AA10or] DH,P,RH

P- ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS
P01- ANTIPROTOZOALS
P01A- AGENTS AGAINST AMOEBIASIS AND OTHER PROTOZOAL DISEASES
Metronidazole 125mg per five milliliter, in 60ml bottle, oral ingestion suspension-syrup-liquid [P01AB01or] BHC,CHC,DP,H,P,RH
Metronidazole 200mg per five milliliter, in 60ml bottle, oral ingestion suspension-syrup-liquid [P01AB01or] BHC,CHC,DP,H,P,RH
Metronidazole 200mg per tablet, oral ingestion tablet-capsule [P01AB01or] BHC,CHC,DP,H,P,RH
Metronidazole 400mg per tablet, oral ingestion tablet-capsule [P01AB01or] BHC,CHC,DP,H,P,RH

P01B- ANTIMALARIALS
Artemether oily 40mg per milliliter, injection solution [P01BE02inj] CHC,DP,H,P,RH
Artemether oily 80mg per milliliter, injection solution [P01BE02inj] CHC,DP,H,P,RH
Artesunate 150mg + Sulphadoxine 500mg + Pyrimethamine 25mg per blister, oral ingestion blister [P01BE53or] BHC,CHC,DP,H,P,RH
Artesunate 300mg + Sulphadoxine 1000mg + Pyrimethamine 50mg per blister, oral ingestion blister [P01BE53or] BHC,CHC,DP,H,P,RH
Artesunate 600mg + Sulphadoxine 1500mg + Pyrimethamine 75mg per blister, oral ingestion blister [P01BE53or] BHC,CHC,DP,H,P,RH
Chloroquine (base) 150mg per tablet, oral ingestion tablet-capsule [P01BA01or] HP,BHC,CHC,DP,H,P,RH

Version of 15 December 2007
Chloroquine (base) 50mg per five milliliter, oral ingestion suspension-syrup-liquid [P01BA01or]
Pyrimethamine 25mg + Sulfadoxin 500mg per tablet, oral ingestion tablet-capsule (PS) [P01BD51or]
Quinine 300mg per milliliter, in 2ml ampoule, injection solution [P01BC01inj]
Quinine 300mg per tablet, oral ingestion tablet-capsule [P01BC01or]

**P01C- AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS**
Meglumine antimonate 30% in 5ml ampoule, injection solution [P01CB01inj]
Sodium stibogluconate 100mg per milliliter, injection solution [P01CB02inj]

**P02- ANTHELMINTICS**
Albendazole 200mg per tablet, oral ingestion chewable tablet [P02CA03or]
Albendazole chew 400mg per tablet, oral ingestion tablet-capsule [P02CA03or]
Diethylcarbamazine citrate 100mg per tablet, oral ingestion tablet-capsule [P02CB02or]
Diethylcarbamazine citrate 50mg per tablet, oral ingestion tablet-capsule [P02CB02or]
Mebendazole 100mg per tablet, oral ingestion chewable tablet [P02CA01or]

**P03- ECTOPARASITICIDES, INCL. SCABICIDES, INSECTICIDES AND REPELLENTS**
Benzoic Acid 6% + Salicylic acid 3%topical cream-ointment-gel [P03AX01]
Lindane 1%topical lotion [P03AB02]

**R- RESPIRATORY SYSTEM**

**R01- NASAL PREPARATIONS**
Beclomethason dipropionate 250mcg per dose, nasal spray [R01AD01ns]
Beclomethason dipropionate 50mcg per dose, nasal spray [R01AD01ns]
Naphazoline 0.05% in 10ml bottle, nasal drop [R01AA08ns]

**R03- DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES**

**R03A- ADRENERGICS, INHALANTS**
Salbutamol 0.1mg per dose, in 200dose bottle, inhalation solution [R03AC02ihas]
Salbutamol 5mg per milliliter, nebulizer solution [R03AC02ihsl]

**R03C- ADRENERGICS FOR SYSTEMIC USE**
Salbutamol 0.05mg per milliliter, in 5ml ampoule, injection ampoule-vial [R03CC02inj] RH
Salbutamol 0.5mg per milliliter, in 1ml ampoule, injection ampoule-vial [R03CC02inj]
Salbutamol 2mg per five milliliter, in 60ml bottle, oral ingestion suspension-syrup-liquid [R03CC02or]
Salbutamol 2mg per tablet, oral ingestion tablet-capsule [R03CC02or] DH, PH, RH
Salbutamol 4mg per tablet, oral ingestion tablet-capsule [R03CC02or] DH, PH, RH

R03D- OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Aminophylline 100mg per tablet, oral ingestion tablet-capsule [R03DA05or] BHC, CHC, DH DH, PH, RH
Aminophylline 25mg per milliliter, in 10ml ampoule, injection solution [R03DA05inj] BHC*, CHC, DH DH, PH, RH

R06- ANTIHISTAMINES FOR SYSTEMIC USE
R06A- ANTIHISTAMINES FOR SYSTEMIC USE
Chlorphenamine maleate 10mg per milliliter, injection ampoule-vial [R06AB04inj] BHC, CHC, DH DH, PH, RH
Chlorphenamine maleate 4mg per tablet, oral ingestion tablet-capsule [R06AB04or] HP, BHC, CHC, DH DH, PH, RH
Dimenhydramine 50mg per tablet, oral ingestion tablet-capsule [R06AA52] DH, PH, RH
Diphenhydramine chloride 25mg per tablet, oral ingestion tablet-capsule [R06AA02orchl] DH, PH, RH
Diphenhydramine chloride 50mg per tablet, oral ingestion tablet-capsule [R06AA02orchl] DH, PH, RH
Diphenhydramine chloride 5mg per five milliliter, oral ingestion suspension-syrup-liquid [R06AA02or] DH, PH, RH
Diphenhydramine benzoate 50mg per tablet, oral ingestion tablet-capsule [R06AA02ortc] DH, PH, RH
Promethazine 25mg per milliliter, in 2ml ampoule, injection solution [R06AD02inj] DH, PH, RH
Promethazine 25mg per tablet, oral ingestion tablet-capsule [R06AD02or] DH, PH, RH
Promethazine 5mg per five milliliter, oral ingestion suspension-syrup-liquid [R06AD02or] DH, PH, RH

S- SENSORY ORGANS
S01- OPHTHALMOLOGICALS
S01A- EYE ANTIINFECTIVES
Aciclovir 3% in 15gr tube, ophthalmologic cream-ointment-gel [S01AD03] DH, PH, RH
Chloramphenicol 0.5% in 2.5ml ampoule, ophthalmologic drop [S01AA01] DH, PH, RH
Gentamicin 0.3% in 5ml bottle, ophthalmologic drop [S01AA11] DH, PH, RH
Sulfacetamide 10% in 15ml bottle, ophthalmologic drop [S01AB04] RH
Sulfacetamide 20% in 15ml bottle, ophthalmologic drop [S01AB04] RH
Tetracycline 1%ophthalmologic cream-ointment-gel [S01AA09] HP, BHC, CHC, DH DH, PH, RH

S01B- EYE ANTIINFLAMMATORY AGENTS

Version of 15 December 2007
Prednisolone 0.5% in 5ml bottle, ophthalmologic drop [S01BA04] RH
Prednisolone 1% in 5ml bottle, ophthalmologic drop [S01BA04]

S01E- ANTIGLAUCOMA PREPARATIONS AND MIOTICS1)
Acetazolamide 250mg per tablet, oral ingestion tablet-capsule [S01EC01or] RH
Pilocarpine 2% in 15ml bottle, ophthalmologic drop [S01EB01] RH
Pilocarpine 4% in 15ml bottle, ophthalmologic drop [S01EB01] RH
Timolol 0.25% in 5ml bottle, ophthalmologic drop [S01ED01] RH
Timolol 0.5% in 5ml bottle, ophthalmologic drop [S01ED01] RH

S01F- MYDRIATICS AND CYCLOPLEGICS
Atropine sulfate 0.1% in 5ml bottle, ophthalmologic drop [S01FA01] RH
Atropine sulfate 0.5% in 3.5ml bottle, ophthalmologic drop [S01FA01] RH
Tropicamide 0.5% in 15ml bottle, ophthalmologic drop [S01FA06] RH
Tropicamide 1% in 3ml bottle, ophthalmologic drop [S01FA06] RH

S01H- EYE LOCAL ANESTHETICS
Tetracaine 0.5% in 15ml bottle, ophthalmologic drop [S01HA03] DH,PH,RH

S01- OTOLOGICALS
S01A- EAR ANTIINFECTIVES
Boric acid (in glycerin) 5% otoologic liquid [S02AA03] RH

V- VARIOUS

V03- ALL OTHER THERAPEUTIC PRODUCTS
V03AA- ANTIDOTES
Acetylcysteine 200mg per five milliliter, oral ingestion suspension-syrup-liquid [V03AB23] RH
Atropine sulfate 1mg per milliliter, in 1ml ampoule, injection ampoule-vial [V03AB29] DH,PH,RH
Deferoxamine mesilate 500mg per vial, injection powder [V03AC01] RH
Dimercaprol (BAL) 100mg per milliliter, in 3ml ampoule, injection solution (BAL) [V03AB09] RH
Dimercaprol (BAL) 50mg per milliliter, injection solution [V03AB09] RH
Flumazenil 0.1mg per milliliter, injection ampoule-vial [V03AB25] DH,PH,RH
Methylene blue (Methylthioninium) 10mg per milliliter, in 10ml ampoule, injection solution [V03AB17] RH
Naloxone 400mcg per milliliter, injection solution [V03AB15] DH,PH,RH

Version of 15 December 2007
Oxygen cubmt per bottle, inhalation gas [V03AN01] BHC,CHC,DH DH,PH,RH
Potassium iodide 60mg per tablet, oral ingestion tablet-capsule [V03AB21] RH
Protamine sulphate 10mg per milliliter, in 5ml ampoule, injection solution [V03AB14] PH,RH

V04- DIAGNOSTIC AGENTS
Tuberculin purified protein derivative 100IU per milliliter, injection solution [V04CF01] DH,PH,RH
Tuberculin purified protein derivative 10IU per milliliter, injection solution [V04CF01] DH,PH,RH

V07- ALL OTHER NON-THERAPEUTIC PRODUCTS
Water for Injection in 10ml ampoule, injection solution [V07AB01] BHC,CHC,DH DH,PH,RH
Water for Injection in 5ml ampoule, injection solution [V07AB01] BHC,CHC,DH DH,PH,RH

V08- CONTRAST MEDIA
V08A- X-RAY CONTRAST MEDIA, IODINATED
Diatrizoic acid meglumine 66% + Diatrizoic acid sodium 10%injection solution (Amidotrizoate) [V08AA01] RH
Diatrizoic acid meglumine 66% + Diatrizoic acid sodium 10%injection solution (Amidotrizoate) [V08AA01] RH

V08B- X-RAY CONTRAST MEDIA, NON-IODINATED
Barium sulfate 30%oral ingestion suspension-syrup-liquid [V08BA01] RH
<table>
<thead>
<tr>
<th>Acronym</th>
<th>ATC</th>
<th>Name</th>
<th>Therapeutic Defined Daily Dose (adult)</th>
<th>Supplement Daily Intake</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vit A</td>
<td>A11CA01</td>
<td>Retinol</td>
<td>inj 50 TU</td>
<td>Min 0.4 Max 1.3 mg</td>
</tr>
<tr>
<td>Vit A</td>
<td>A11CA01</td>
<td>Retinol</td>
<td>oral 50 TU</td>
<td>Min 0.4 Max 1.3 mg</td>
</tr>
<tr>
<td>Vit B1**</td>
<td>A11DA01</td>
<td>Thiamine**</td>
<td>inj 50 mg</td>
<td>Min 0.4 Max 1.4 mg</td>
</tr>
<tr>
<td>Vit B1**</td>
<td>A11DA01</td>
<td>Thiamine**</td>
<td>oral 50 mg</td>
<td>Min 0.4 Max 1.4 mg</td>
</tr>
<tr>
<td>Vit B12**</td>
<td>B03BA04</td>
<td>Cobamamide**</td>
<td></td>
<td>Min 0.4 Max 2.8 mcg</td>
</tr>
<tr>
<td>Vit B12**</td>
<td>B03BA01</td>
<td>Cyanocobalamin**</td>
<td>nas 0.07 mg</td>
<td>Min 0.4 Max 2.8 mcg</td>
</tr>
<tr>
<td>Vit B12**</td>
<td>B03BA01</td>
<td>Cyanocobalamin**</td>
<td>oral 1 mg</td>
<td>Min 0.4 Max 2.8 mcg</td>
</tr>
<tr>
<td>Vit B12**</td>
<td>B03BA01</td>
<td>Cyanocobalamin**</td>
<td>inj 0.02 mg</td>
<td>Min 0.4 Max 2.8 mcg</td>
</tr>
<tr>
<td>Vit B12**</td>
<td>B03BA03</td>
<td>Hydroxocobalamin**</td>
<td>inj 0.02 mg</td>
<td>Min 0.4 Max 2.8 mcg</td>
</tr>
<tr>
<td>Vit B12**</td>
<td>B03BA05</td>
<td>Mecobalamin**</td>
<td>oral 1.5 mg</td>
<td>Min 0.4 Max 2.8 mcg</td>
</tr>
<tr>
<td>Vit B12**</td>
<td>B03BA05</td>
<td>Mecobalamin**</td>
<td>inj 0.2 mg</td>
<td>Min 0.4 Max 2.8 mcg</td>
</tr>
<tr>
<td>Vit B2**</td>
<td>A11HA04</td>
<td>Riboflavin**</td>
<td></td>
<td>Min 0.3 Max 1.6 mg</td>
</tr>
<tr>
<td>Vit B3**</td>
<td>A11HA01</td>
<td>Nicotinamide**</td>
<td>oral 150 mg</td>
<td>Min 2 Max 17 mg</td>
</tr>
<tr>
<td>Vit B5**</td>
<td>A11HA31</td>
<td>Calcium pantothenate**</td>
<td></td>
<td>Min 1.7 Max 7 mg</td>
</tr>
<tr>
<td>Vit B5**</td>
<td>A11HA30</td>
<td>Dexpantenol**</td>
<td></td>
<td>Min 1.7 Max 7 mg</td>
</tr>
<tr>
<td>Vit B5**</td>
<td>A11HA32</td>
<td>Pantethine**</td>
<td></td>
<td>Min 1.7 Max 7 mg</td>
</tr>
<tr>
<td>Vit B6**</td>
<td>A11HA06</td>
<td>Pyridoxal phosphate**</td>
<td></td>
<td>Min 0.1 Max 2 mg</td>
</tr>
<tr>
<td>Vit B6**</td>
<td>A11HA02</td>
<td>Pyridoxine**</td>
<td>oral 160 mg</td>
<td>Min 0.1 Max 2 mg</td>
</tr>
<tr>
<td>Vit B6**</td>
<td>A11HA02</td>
<td>Pyridoxine**</td>
<td>inj 160 mg</td>
<td>Min 0.1 Max 2 mg</td>
</tr>
<tr>
<td>Vit B7**</td>
<td>A11HA05</td>
<td>Biotin**</td>
<td></td>
<td>Min 5 Max 35 mcg</td>
</tr>
<tr>
<td>Vit B8**</td>
<td>A11HA07</td>
<td>Inositol**</td>
<td></td>
<td>Min 5 Max 15 mcg</td>
</tr>
<tr>
<td>Vit B9**</td>
<td>B03BB01</td>
<td>Folic Acid** (prophylaxis)</td>
<td>oral 0.4 mg</td>
<td>Min 0.065 Max 0.5 mg</td>
</tr>
<tr>
<td>Vit B9**</td>
<td>B03BB01</td>
<td>Folic Acid** (therapy)</td>
<td>inj 10 mg</td>
<td>Min 0.065 Max 0.5 mg</td>
</tr>
<tr>
<td>Vit C**</td>
<td>A11GA01</td>
<td>Ascorbic acid**</td>
<td>inj 200 mg</td>
<td>Min 40 Max 120 mg</td>
</tr>
<tr>
<td>Vit C**</td>
<td>A11GA01</td>
<td>Ascorbic acid**</td>
<td>oral 200 mg</td>
<td>Min 40 Max 120 mg</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC03</td>
<td>Alfalcacidol</td>
<td>oral 0.001 mg</td>
<td>Min 0.001 mg</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC03</td>
<td>Alfalcacidol</td>
<td>inj 0.001 mg</td>
<td>Min 0.001 mg</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC06</td>
<td>Calcifiediol</td>
<td></td>
<td>Min 5 Max 15 mcg</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC04</td>
<td>Calcirol</td>
<td>oral 0.001 mg</td>
<td>Min 0.001 mg</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC04</td>
<td>Calcirol</td>
<td>inj 0.001 mg</td>
<td>Min 0.001 mg</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC05</td>
<td>Colecalciferol</td>
<td></td>
<td>Min 5 Max 15 mcg</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC02</td>
<td>Dihydrotachysterol</td>
<td>oral 1 mg</td>
<td>Min 5 Max 15 mcg</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC01</td>
<td>Ergocalciferol</td>
<td></td>
<td>Min 5 Max 15 mcg</td>
</tr>
<tr>
<td>Vit D</td>
<td>A11CC07</td>
<td>Paricalcitol</td>
<td></td>
<td>Min 5 Max 15 mcg</td>
</tr>
<tr>
<td>Vit E</td>
<td>A11HA03</td>
<td>Tocopherol</td>
<td>oral 200 mg</td>
<td>Min 4 Max 19 mg</td>
</tr>
<tr>
<td>Vit E</td>
<td>A11HA03</td>
<td>Tocopherol</td>
<td>inj 200 mg</td>
<td>Min 4 Max 19 mg</td>
</tr>
<tr>
<td>Vit K3</td>
<td>B02BA02</td>
<td>Menadione</td>
<td>oral 10 mg</td>
<td>Min 0.02 Max 0.09 mcg</td>
</tr>
<tr>
<td>Vit K3</td>
<td>B02BA02</td>
<td>Menadione</td>
<td>inj 2 mg</td>
<td>Min 0.02 Max 0.09 mcg</td>
</tr>
<tr>
<td>Vit K3</td>
<td>B02BA01</td>
<td>Phytomenadione</td>
<td>oral 20 mg</td>
<td>Min 0.02 Max 0.09 mcg</td>
</tr>
<tr>
<td>Vit K3</td>
<td>B02BA01</td>
<td>Phytomenadione</td>
<td>inj 20 mg</td>
<td>Min 0.02 Max 0.09 mcg</td>
</tr>
</tbody>
</table>

Version of 15 December 2007
<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Iodine</td>
<td>0.09</td>
<td>0.29</td>
</tr>
<tr>
<td>Iron</td>
<td>0.27</td>
<td>9</td>
</tr>
<tr>
<td>Magnesium</td>
<td>0.08</td>
<td>0.32</td>
</tr>
<tr>
<td>Manganese</td>
<td>0.003</td>
<td>2.6</td>
</tr>
<tr>
<td>Molybdenum</td>
<td>0.017</td>
<td>0.05</td>
</tr>
<tr>
<td>Phosphorus</td>
<td>450</td>
<td>700</td>
</tr>
<tr>
<td>Selenium</td>
<td>0.02</td>
<td>0.07</td>
</tr>
<tr>
<td>Zinc</td>
<td>2</td>
<td>12</td>
</tr>
</tbody>
</table>

**Water soluble vitamins can exceed maximum strengths up to 20%**

National Family Planning Program List

Items on the National Family Planning Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS/EPHS.

G02- OTHER GYNECOLOGICALS
G02B- CONTRACEPTIVES FOR TOPICAL USE
Condom w/wo nonoxinol 1pce per piece, topical piece
Intrauterine device with copper 1pce per piece, vaginal intra uterine device

G03- SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
G03A- HORMONAL CONTRACEPTIVES FOR SYSTEMIC USE
Ethinylestradiol 0.035mg + Norethisterone 1mg per tablet, oral ingestion tablet-capsule
Ethinylestradiol 0.03mg + Levonorgestrel 0.15mg per tablet, oral ingestion tablet-capsule
Ethinylestradiol 0.03mg + Norgestrel 0.3mg per tablet, oral ingestion tablet-capsule
Medroxyprogesterone acetate Depot 150mg per milliliter, in 1ml vial, injection solution
Norgestrel 0.075mg per tablet, oral ingestion tablet-capsule

National Post Partum Hemorrhage Program List

Items on the National Post Partum Hemorrhage Program List can be imported and used only with explicit written approval and under supervision of the MOPH National Post Partum Hemorrhage Program, under DG Reproductive Health. The items included in this list are not for general and/or commercial use in the private sector.

G02- OTHER GYNECOLOGICALS
G02A- OXYTOCICS
Dinoprostone 2mg per capsule, vaginal tablet-capsule
Dinoprostone 3mg per tablet, oral ingestion tablet-capsule
Misoprostol 200mcg per tablet, oral ingestion tablet-capsule
Misoprostol 25mcg per tablet, vaginal tablet-capsule

Version of 15 December 2007
National HIV/AIDS Program List

Items on the National HIV/AIDS Program list can be imported and used by the private and public sector. They should only be dispensed on prescription. In public sector health facilities, they should be used as per specifications in the BPHS/EPHS.

J05- ANTIVIRALS FOR SYSTEMIC USE

J05A- DIRECT ACTING ANTIVIRALS

Abacavir 100mg per five milliliter, oral ingestion solution (ABC)
Abacavir 300mg per tablet, oral ingestion tablet-capsule (ABC)
Atazanavir 300mg + Ritonavir per tablet, oral ingestion tablet-capsule (ATVRTV)
Didanosine 100mg per sachet, oral ingestion powder (ddl)
Didanosine 100mg per tablet, oral ingestion chewable tablet (ddl)
Didanosine 125mg per capsule, oral ingestion (ddl)
Didanosine 150mg per tablet, oral ingestion chewable tablet (ddl)
Didanosine 167mg per sachet, oral ingestion solution (ddl)
Didanosine 200mg per capsule, oral ingestion (ddl)
Didanosine 200mg per tablet, oral ingestion chewable tablet (ddl)
Didanosine 250mg per capsule, oral ingestion (ddl)
Didanosine 25mg per tablet, oral ingestion chewable tablet (ddl)
Didanosine 50mg per tablet, oral ingestion chewable tablet (ddl)
Didanosine 100mg per capsule, oral ingestion (ddl)
Efavirenz 100mg per capsule, oral ingestion tablet-capsule (EFV)
Efavirenz 150mg per five milliliter, oral ingestion liquid (EFV)
Efavirenz 200mg per capsule, oral ingestion tablet-capsule (EFV)
Efavirenz 50mg per capsule, oral ingestion tablet-capsule (EFV)
Efavirenz 600mg + Emtricitabine 200mg + Tenofovir 300mg per tablet, oral ingestion tablet-capsule (EFVFTCTDF)
Efavirenz 600mg per tablet, oral ingestion tablet-capsule (EFV)
Emtricitabine 200mg + Tenofovir 300mg per tablet, oral ingestion tablet-capsule (FTCTDF)
Emtricitabine 200mg per capsule, oral ingestion tablet-capsule (FTC)
Emtricitabine 50mg per five milliliter, oral ingestion liquid (FTC)
Indinavir 200mg per capsule, oral ingestion tablet-capsule (IDV)
Indinavir 333mg per capsule, oral ingestion tablet-capsule (IDV)
Indinavir 400mg per capsule, oral ingestion tablet-capsule (IDV)
Lamivudine 100mg per tablet, oral ingestion tablet-capsule (3TC)
Lamivudine 150mg per tablet, oral ingestion tablet-capsule (3TC)
Lamivudine 300mg per tablet, oral ingestion tablet-capsule (3TC)
Lamivudine 50mg per five milliliter, oral ingestion suspension-syrup-liquid (3TC)
Lopinavir 133.3mg + Ritonavir 33.3mg per capsule, oral ingestion tablet-capsule (LPVr)
Lopinavir 400mg + Ritonavir 100mg per five milliliter, oral ingestion liquid (LPVr)
Nelfinavir 200mg per five milliliter, oral ingestion suspension-syrup-liquid (NFV)
Nelfinavir 250mg per tablet, oral ingestion tablet-capsule (NVF)
Nelfinavir 50mg per pack, oral ingestion powder (NVF)
Nelfinavir 625mg per tablet, oral ingestion tablet-capsule (NFV)
Nevirapine 200mg per tablet, oral ingestion tablet-capsule (NVP)
Nevirapine 50mg per five milliliter, oral ingestion liquid (NVP)
Ritonavir 100mg per tablet, oral ingestion tablet-capsule (RTV)
Ritonavir 400mg per five milliliter, oral ingestion liquid (RTV)
Saquinavir 200mg per capsule, oral ingestion tablet-capsule (SQV)
Stavudine 15mg per tablet, oral ingestion tablet-capsule (d4T)
Stavudine 20mg per tablet, oral ingestion tablet-capsule (d4T)
Stavudine 30mg + Lamivudine 150mg + Nevirapine 200mg per tablet, oral ingestion tablet-capsule

Version of 15 December 2007
(d4T3TCNVP)
Stavudine 30mg per tablet, oral ingestion tablet-capsule (d4T)
Stavudine 40mg per tablet, oral ingestion tablet-capsule (d4T)
Stavudine 5mg per five milliliter, oral ingestion liquid (d4T)
Tenofovir 300mg per tablet, oral ingestion tablet-capsule (TDF)
Zidovudine 100mg per capsule, oral ingestion tablet-capsule (AZT)
Zidovudine 10mg per milliliter, injection solution (AZT)
Zidovudine 250mg per capsule, oral ingestion tablet-capsule (AZT)
Zidovudine 300mg + Lamivudine 150mg + Nevirapine 200mg per tablet, oral ingestion tablet-capsule
(ZT3TCNVP)
Zidovudine 300mg + Lamivudine 150mg per tablet, oral ingestion tablet-capsule (AZT3TC)
Zidovudine 50mg per five milliliter, oral ingestion liquid (AZT)

National Dependency Substitution Program List

Items on the National Substance Dependency Program can be imported and used only with explicit written approval of the MOPH National Substance Dependency Program. The items included in this list are not for general and/or commercial use in the private sector.

N07- OTHER NERVOUS SYSTEM DRUGS
N07B- DRUGS USED IN ADDICTIVE DISORDERS
Buprenorphine 2mg per tablet, oral ingestion tablet-capsule
Buprenorphine 8mg per tablet, oral ingestion tablet-capsule
Methadone 10mg per milliliter, in 1ml ampoule, injection solution
Methadone 10mg per milliliter, oral ingestion solution
Methadone 10mg per tablet, oral ingestion tablet-capsule
Methadone 5mg per milliliter, oral ingestion solution
Methadone 5mg per tablet, oral ingestion tablet-capsule
Opium tincture 10% oral ingestion solution

Version of 15 December 2007
National Malaria and Leishmania Program List

Items on the National Malaria and Leishmania Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS/EPHS.

P01B- ANTIMALARIALS

Artemether oily 40mg per milliliter, injection solution
Artemether oily 80mg per milliliter, injection solution
Artesunate 150mg + Sulfadoxine 500mg + Pyrimethamine 25mg per blister, oral ingestion blister
Artesunate 300mg + Sulfadoxine 1000mg + Pyrimethamine 50mg per blister, oral ingestion blister
Artesunate 600mg + Sulfadoxine 1500mg + Pyrimethamine 75mg per blister, oral ingestion blister
Chloroquine (base) 150mg per tablet, oral ingestion tablet-capsule
Chloroquine (base) 50mg per five milliliter, oral ingestion suspension-syrup-liquid
Primaquine 7.5 mg per tablet, oral ingestion tablet-capsule (specialized use)
Pyrimethamine 25mg + Sulfadoxin 500mg per tablet, oral ingestion tablet-capsule (PS)
Quinine 300mg per milliliter, in 2ml ampoule, injection solution
Quinine 300mg per tablet, oral ingestion tablet-capsule

P01C- AGENTS AGAINST LEISHMANIASIS AND TRYPANOSOMIASIS

Meglumine antimonate 30% in 5ml ampoule, injection solution
Sodium stibogluconate 100mg per milliliter, injection solution
National Tuberculosis Program List

Items on the National Tuberculosis Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS/EPHS.

**J04- ANTIMYCOBACTERIALS**

**J04A- DRUGS FOR TREATMENT OF TUBERCULOSIS**

- Ethambutol 400mg + Isoniazid 75mg per tablet, oral ingestion tablet-capsule (EH)
- Ethambutol 400mg per tablet, oral ingestion tablet-capsule (E)
- Isoniazid 100mg per tablet, oral ingestion tablet-capsule (H)
- Isoniazid 300mg per tablet, oral ingestion tablet-capsule
- Isoniazid 50mg per tablet, oral ingestion tablet-capsule (H)
- Pyrazinamide 150mg per tablet, oral ingestion tablet-capsule (Z)
- Pyrazinamide 400mg per tablet, oral ingestion tablet-capsule (Z)
- Pyrazinamide 500mg per tablet, oral ingestion tablet-capsule (Z)
- Rifampicin 100mg per five milliliter, oral ingestion suspension-syrup-liquid (R)
- Rifampicin 150mg + Isoniazid 75mg + Ethambutol 275mg per tablet, oral ingestion tablet-capsule (RHE)
- Rifampicin 150mg + Isoniazid 75mg + Pyrazinamide 400mg + Ethambutol 275mg per tablet, oral ingestion tablet-capsule (RHE)
- Rifampicin 150mg + Isoniazid 75mg per tablet, oral ingestion tablet-capsule (RH)
- Rifampicin 300mg per capsule, oral ingestion tablet-capsule
- Clofazimine 100mg per capsule, oral ingestion tablet-capsule
- Clofazimine 50mg per capsule, oral ingestion tablet-capsule
- Dapsone 100mg per tablet, oral ingestion tablet-capsule
- Dapsone 25mg per tablet, oral ingestion tablet-capsule
- Dapsone 50mg per tablet, oral ingestion tablet-capsule
- Rifampicin 150mg + Dapsone 50mg + Clofazimine 50mg per tablet, oral ingestion tablet-capsule (R)
- Rifampicin 600mg + Dapsone 100mg + Clofazimine 50mg per tablet, oral ingestion tablet-capsule (R)
- Streptomycin 1gr per vial, injection ampoule-vial (S)

National Leprosy Program List

Items on the National Leprosy Program list can be imported and used by the private and public sector. In public sector health facilities, they should be used as per specifications in the BPHS/EPHS.

**J04- ANTIMYCOBACTERIALS**

- Rifampicin 150mg per tablet, oral ingestion tablet-capsule (R)
- Rifampicin 300mg per capsule, oral ingestion tablet-capsule (R)
- Clofazimine 100mg per capsule, oral ingestion tablet-capsule
- Clofazimine 50mg per capsule, oral ingestion tablet-capsule
- Dapsone 100mg per tablet, oral ingestion tablet-capsule
- Dapsone 25mg per tablet, oral ingestion tablet-capsule
- Dapsone 50mg per tablet, oral ingestion tablet-capsule
- Rifampicin 300mg + Dapsone 50mg + Clofazimine 50mg per tablet, oral ingestion tablet-capsule (R)
- Rifampicin 600mg + Dapsone 100mg + Clofazimine 50mg per tablet, oral ingestion tablet-capsule (R)
ANNEX 1:  
Procedure for Application for Inclusion of Medicines on the Essential Drugs List of the Ministry of Public Health of Afghanistan

A. General

The Essential Drugs List (EDL) selection process is based upon a well-developed procedure, that ensures transparency of the inclusion process.

Applications for inclusion in the EDL will only be considered if application form has been fully completed for each proposed drug. There is one application form to be filled out for each proposed drug. Only for drugs already on the LDL list can an application for inclusion in EDL be submitted. In case of urgent and compelling reasons for inclusion of a drug in the EDL list, both the request for inclusion in LDL and EDL can be submitted at the same time: they will be processed at the same time. In summary, the necessary information required before an application for inclusion in the EDL will be considered is as follows:

1. The applicant’s contact details are complete;
2. The drug’s international non-propriety name (INN) has been stated, including strength, route of administration, and presentation;
3. The indications have been clearly stated;
4. The details of the proposed regimen for each indication are clearly stated;
5. All relevant comparator drugs presently included in the EDL have been listed for each indication;
6. There is sufficient evidence to support the proposed amendment;
7. A supporting letter of the relevant MOPH department or program is included.

B. Types of applications

Applications may address major or minor amendments.

Minor amendments include, but are not limited to:
1. new strengths, presentations or administration forms of drugs already included in the EDL
   E.g. proposing the inhalator form of a bronchodilator that is already included as tablet and/or injection
   E.g. slow-release tablets instead of common tablets
2. combination therapies of drugs already included in the EDL

For minor amendments the required supporting evidence should be relevant to the nature of the amendment, and include cost implications.
E.g. alignment with new WHO recommendations on strengths or combination therapies do not require only a copy of the new WHO recommendations.

Major amendments include, but are not limited to:

1 The same format is used for proposing deletions from the list. Often the proposal for inclusion of one drug will also indicate the drug to be replaced with that drug. The drug to be replaced will be deleted. If an existing drug should be deleted without replacement, the same format can be used, indicating the drug to be deleted in Section 4 without however proposing a new drug for replacement in Section 3, but mentioning “to be removed” in Section 3.
1. new indications for existing items on the list  
   E.g. using a drug included for its anti-hypertension properties as a tocolytic
2. new therapeutic entities  
   E.g. a new antibiotic (doxycycline) to replace an previously included one (tetracycline) for the same indication.
3. new therapeutic classes  
   E.g. anti-retroviral drugs

All major amendments must be supported by evidence reflecting safety, efficacy and cost of the medicine compared to an already listed drug for the same indication. For inclusion of drugs already accepted in the LDL list, reference to new MOPH guidelines, in line with WHO recommended practices may be sufficient. If the drug is not on the LDL list, please refer to the instructions in the application form <name>, no. <number>, for inclusion of drugs in the LDL list.

C. Submittal and screening process

Applications are submitted to the GD Pharmacy of the MOPH. Upon receipt, the GD will acknowledge the receipt of the application in writing.

Applications are screened by the Technical Subcommittee (TSC) of the National Essential Drugs List Committee (NEDLC) at the GD Pharmacy at the MOPH to ensure that:

1. the applicant’s contact details are included
2. the drug can be identified in terms of the INN (generic name)
3. at least one indication has been included, with the proposed regimen and cost;
4. relevant comparator drug(s) ha(s)(ve) been identified with their corresponding dosing regimen;
5. the cited evidence to substantiate the application are valid
6. a supporting letter of the relevant MOPH department or program is included.

TSC will compile a review of the prevailing cost of therapy and allocates the application to a suitably qualified reviewer who compiles a technical report. This technical report summarizes a review of the submitted data and supporting references in terms of the following:

1. relative safety – are side-effects acceptable considering the benefits for the patient having the indicated condition
2. relative efficacy – compare treatment results with treatment results of existing drugs for the stated condition
3. practice environment – the focus here being efficacy relative to current LDL drugs
4. pharmaco-economic evaluation – compare the full treatment cost of the proposed drug with the full treatment cost of existing drugs

The report is then presented to the technical subcommittee. The committee may request further information from the applicant before recommending a decision to the NEDLC.

The technical subcommittee will make recommendations to the NEDLC for approval or rejection. Where the NEDLC is of the opinion that further review is required, the decision will be sent back to the technical subcommittee for further review.

Where the NEDLC is of the opinion that the drug is acceptable, the recommendation for approval will be submitted to the National Medicine Board.

Where the NEDLC is of the opinion that the drug is not acceptable, the applicant will be informed of the rejection and of the reasons for rejection. Resubmission requires significant additional information and supporting references that address the specific reason(s) for rejection of the original application.

D. Detailed description of the data elements of the application form <name>, no. <number>
The application submission form is divided into 5 sections.

Section 1: Proposed Drug Identification

a) **Proposed Drug:** The International Nonproprietary Name (INN) of the medicine – this identifies a pharmaceutical substance or active pharmaceutical ingredient by a unique name that is globally recognized and is public property. A nonproprietary name is also known as a generic name. It also includes the presentation form and the strength of the proposed medicine. E.g. Acetylsalicylic acid, tablet, 325 mg.

b) **Level of Care** - indicate whether the proposed medicine should be included in the BPHS, indicating the specific level(s), and/or the EPHS, also indicating the specific level(s). If intended for use by a special program, or specialist MD, indicate the program or MD in the Special: case

C) **Submission date** – the Shamsi calendar date on which the submission is filled out.

Section 2: Applicant’s Details

The NEDLC will acknowledge all submissions and communicate decisions with supporting arguments where appropriate. This section therefore forms a vital link between the applicant and the decision making process.

a) **Title** – Mr, Mrs, Dr, Pr, etc….

b) **Name** – full name of the applicant. Do not abbreviate: Mohammad, but not Mhd.; Sayyed, but not S.; etc…

c) **Father’s Name** - full name of the applicant’s father. Do not abbreviate: Mohammad, but not Mhd.; Sayyed, but not S.; etc…

e) **Postal address** – full address where correspondence regarding the application should be sent: house #, street name, village of city nahia, district and province

f) **Phone** – Phone number(s) on which the applicant can be contacted.

g) **E-mail** – email address where correspondence regarding the application can be sent

d) **Facility ID** – if applicable, the official MOPH facility code of the facility where the applicant works. If the applicant is a private practitioner, working in a non-registered facility, put “NA” for this entry.

Section 3: Proposed Indications

For each drug submitted for inclusion, at least one indication with proposed regimen needs to be filled out. Up to three indications can be filled out for one drug submitted for inclusion.

a) **Indication** – the applicant can list up to 3 indications (conditions) for using the suggested drug. Points to consider:
   i. Where the applicant suggests a new therapeutic class, i.e. a new or emerging disease/condition, a brief motivation based upon Afghan epidemiological data, as well as inclusion status in BPHS/EPHS or MOPH special program must be included as an annexure.
   ii. The indication should allow for the identification of the appropriate comparator(s) in the current EDL.
   iii. Many drugs have multiple indications. However, not all indications are equally cost effective.

b) **Proposed Treatment Regimen:**
   - **Dose** – the amount of the drug to be given with each intake/administration
   - **Route** – oral, parenteral, topical, etc…
   - **Interval** – expressed as one administration every so many hours
   - **Days** – number of days for a full treatment. For chronic conditions, write “30”

Version of 15 December 2007
The above data will be used for cost comparison and is very important for the pharmaco-economic evaluation of the application.

c) Cost assessment

Costs are expressed in USD – only one currency should be used. Using USD may facilitate comparisons with drugs available on the international market! The cost assessment of the proposed drug is filled out by the applicant and will be double-checked by the TSC.

- **Cost/Unit** – the cost for one unit of the drug. Clearly indicate the unit for which the cost is given.
- **Cost/Day** – the cost for one day of treatment with the drug.
- **Cost/Course** – the cost for a complete treatment, or for one month’s treatment for drugs used in chronic conditions.

The above information is necessary for the determination of affordability. The EDL includes all drugs that are recommended for use in the public sector and eligible for subsidy to decrease costs for the patient and increase access to the drugs for the poor. For this reason, pharmaco-economic data is considered mandatory before deciding to include a drug in the EDL.

d) Evidence

Indicate for each indication the reference of the evidence that supports the use of the proposed drug for that indication. Often this will be the relevant WHO document, or a document from another internationally accepted reference.

Section 4: Drugs on the current EDL for the same indication

As a principle, the addition of an EDL item should replace an existing item. This is of particular importance when safety and economic implications are taken into account. For each indication, the applicant will give at least one comparator drug. For new therapeutic classes, a comparator drug is not required. Details of the comparator drug include:

a) **Drug** – INN (generic name), presentation form and strength.
b) **Indication** – cite (one of) the indication(s) listed in Section 3
b) **Current treatment regimen** – like for the proposed drug
c) **Cost assessment** – the cost assessment of the comparator drugs is done by the TSC
c) **Can be replaced by the proposed drug** – the TSC’s conclusion of the comparison between current drug and the proposed drug (Yes/No)

Section 5: Pharmacy Department Only

This section is intended to ensure that the submissions follow the proper process. Dates of steps/decisions will be noted as appropriate. The section will allow the interested parties to quickly review the history of an application.

**Application number**: upon receipt, the serial number of the application is noted. It consists of the <number of the form>/ <the four digits of the year of submission> / <the serial number of submission in that year>

a) **Correspondence**

- **Date received** – date on which the application was received
- **Date acknowledged** – date on which a message was sent to the initiator confirming receipt
- **Application for additional evidence** – if applicable, date on which a request for more evidence was sent to the applicant. Failure to submit convincing evidence will lead to rejection of the application for inclusion.
- **Supporting letter from**: – the name of the MOPH department or program that supports the application for inclusion in the EDL
Initial evidence – number of name of the reference given as initial evidence
Additional evidence – number of name of the reference given as additional evidence

b) Advice of TSC – if “Accept” or “Reject”
c) Reason for application – summarizes the reason(s) for the application. More than one option may be circled:
   New drug - this is an application for a new drug which is not yet on the EDL
   New strength-presentation form – this is an application for a new strength or presentation form of a drug already included in the EDL
   New or changed condition – this is an application to extend the use of an existing drug to a condition for which it was previously not used, or the condition it was previously accepted for has been changed (e.g. split in two or more new conditions)
   Change in STG – this an application provoked by a change in Standard Treatment Guidelines or official MOPH protocols
   New therapeutic class – this is an application for new drugs that address newly emergent conditions (e.g. HIV/AIDS drugs).

c) Rejected by NCEDL – date on which NEDCL rejected the application
d) Forward to NMB - date on which NEDCL forwarded the application for final acceptance
e) Accepted by NMB - date on which NMB accepted the drug for inclusion
f) Rejected by NMB - date on which NMB rejected the drug for inclusion
e) Signature and stamp of DG Pharmacy - (president of NCEDL) and stamp
f) Signatures and stamp - signatures of members of the NMB

The applicant will be informed in writing of the final decision.
Applicant submits application to DG Pharmacy →

DG Pharmacy checks completeness of application →

Relevant data in Section 1, 2, 3 is complete? →

Mentioned evidence is attached? →

TSC reviews evidence →

Additional evidence needed? →

Application rejected? →

NMB reviews recommendation for acceptance →

Application accepted? →

Drug included in EDL
Notes:

1. Evidence
Evidence is a vital component of the submission and review process. Evidence does not constitute a drug decision and merely informs the strength of the argument. It forms the basis upon which the decision is made and allows for transparent scrutiny of the decision as well as facilitating the review. Evidence is required in support of:
   • relative efficacy
   • relative safety
   • relative safety
   • pharmacoeconomic benefits

Evidence needs to be relevant to the Afghan context. Multinational or foreign studies must be supported by a motivation of the relevance of both the outcome measures as well as socio-economic facets to the Afghan context. The inclusion of at least one relevant reference is mandatory.

For application of an existing drug to a new indication, or introduction of a new drug or new class of drugs, a copy of the full journal article should be included in order to expedite the review process.

2. Communication of decision
After processing, the decision regarding an application will be communicated in writing to the initiator. In case of rejection of the application, the exact reasons for rejection will be mentioned.

3. Reconsidering a rejected application
As a rule, a rejected application will not be reconsidered within six months after the rejection. To qualify for reconsideration, compelling additional evidence (see note 1) should accompany the resubmission.
### Section 1 – Proposed Drug Identification

**Proposed Drug** (INN + form + strength)

<table>
<thead>
<tr>
<th>Level of Care</th>
<th>BPHS</th>
<th>HP</th>
<th>BHC</th>
<th>CHC</th>
<th>DH</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPHS</td>
<td>DH</td>
<td>PH</td>
<td>RH</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Special:**

**Postal Address:**

**Proposed Drug** (INN + form + strength)

<table>
<thead>
<tr>
<th>BPHS</th>
<th>HP</th>
<th>BHC</th>
<th>CHC</th>
<th>DH</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Submission Date:**

**Facility ID:**

### Section 2 - Applicant’s details

<table>
<thead>
<tr>
<th>Title:</th>
<th>Name:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Father’s Name:</th>
<th>Postal Address:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Phone:</th>
<th>E-mail:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Section 3 – Proposed Indications

**Indication**

<table>
<thead>
<tr>
<th>Proposed Regimen</th>
<th>Cost assessment</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose</td>
<td>Route</td>
<td>Interval</td>
</tr>
<tr>
<td>-------</td>
<td>-------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Section 4 – Drugs on current EDL with the Same Indication

<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
<th>Current Regimen</th>
<th>Cost assessment</th>
<th>Can be replaced by proposed drug</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Dose</td>
<td>Route</td>
<td>Interval</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Section 5 – For use by Pharmacy Department Only

**Application number:** ……/…../……..  
**Correspondence**

<table>
<thead>
<tr>
<th>Date Received</th>
<th>Acknowledged</th>
<th>Application for more evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>

**Supporting letter from:**

**Initial evidence:**

**Advice of TSC:** Accept / Reject

<table>
<thead>
<tr>
<th>Reason for application:</th>
<th>New Drug</th>
<th>New strength-form-presentation</th>
<th>New or Changed Condition</th>
<th>New therapeutic class</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>/</td>
<td>/</td>
<td>/</td>
</tr>
</tbody>
</table>

**Rejected by NCEDL:** / /  
**Forward to NMB:** / /  
**Accepted by NMB:** / /  
**Rejected by NMB:** / /  

**Signature and stamp of DG Pharm:**

**Signature and stamp of NMB:**
Consulted literature:


Licensed Drugs List of Afghanistan, Drugs & Therapeutics Committee, Essential Drugs Department, Ministry of Health, Ministry of Public Health, Islamic Republic of Afghanistan, 2005


The Essential Package of Hospital Services for Afghanistan, Ministry of Public Health, Islamic Republic of Afghanistan, 2005

The Interagency List of Essential Medicines for Reproductive Health, World Health Organization, International Planned Parenthood Federation, John Snow Inc.

WHO Model Formulary, 2006,

This publication was prepared by the Ministry of Public Health of the Islamic Republic of Afghanistan with technical and financial assistance from the World Health Organization, Eastern Mediterranean Regional Office, and the people of the United States of America through the United States Agency for International Development under the Technical Support to the Central and Provincial Ministry of Public Health project, Associate Cooperative Agreement No 306-A-00-06-00522-00, through the Leadership, Management and Sustainability program, implemented by Management Sciences for Health.